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        Lithium is one of the most effective treatments for bipolar disorder (BD) and is 
typically recommended as first-line therapy.  However, the efficacy of lithium varies 
widely from person to person, with about 30% of patients showing partial response and 
another 25% no response.  As a result, it would be beneficial to identify factors which 
predict who may respond better than others so treatment could be targeted to the 
appropriate patients.  A growing body of evidence suggests that demographic, clinical, and 
genetic factors may play a role in determining the variability in treatment response.  These 
studies, however, have typically been retrospective or were not specifically designed to 
examine predictors of response, and the results have been inconsistent. 
        This thesis examines the role of lithium in the treatment of BD and seeks to identify 
clinical and genetic predictors that may be used to help guide personalized treatment 




of the thesis is a characterization of trends in lithium utilization for the treatment of BD in 
the U.S. over the past twenty years.  To analyze the  
changing patterns in the management of BD, we use data from the National Ambulatory 
Medical Care Survey and examined trends in prescriptions of lithium along with other 
medication categories in visits for BD. 
        The second contribution of the thesis is an evaluation of clinical predictors associated 
with response to lithium treatment over time.  Using prospective treatment data from the 
Pharmacogenomics of Bipolar Disorder (PGBD) study, we sought to identify clinical 
predictors of lithium response in an attempt to determine the clinical characteristics of 
lithium responders and non-responders prior to initiating treatment. 
        The third contribution of the thesis is to examine genetic predictors of response to 
lithium.   Using genetic data from the PGBD and reference expression quantitative trait 
loci (eQTL) data derived from brain samples from the Lieber Institute for Brain 
Development, we tested for polygenic risk scores as predictors of lithium response, and we 
used a novel application of the transcriptome-wide association (TWAS) approach to 
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        Bipolar disorder (BD) is a severe and often disabling psychiatric disorder that affects 
approximately 1% to 4.4% [1, 2] of the world’s population.  BD is classically described as 
having a course of illness that alternates between extreme mood states of mania and 
depression with episodic relapses and more longstanding disability [3].  BD is a major 
cause of hospitalizations and health care expenditures, and is also associated with an 
increased risk of suicide [4], leading to the critical issue of bipolar treatment.   
        Lithium is one of the most effective treatments for BD [5, 6], and it is typically 
recommended as a first-line therapy [7].  However, the efficacy of lithium can vary widely 
from person to person, with about 30% fully responding (Alda, 2017), while about 30% 
show only partial response and another 25% no response [8].  Moreover, lithium is 




regularly monitored during care to avoid lithium toxicity, which can be life-threatening in 
rare cases.  Concerns about these side-effects and the presumed challenge in managing 
patients while on lithium have led clinicians to increasingly prescribe other anticonvulsants 
and/or second-generation antipsychotics which have demonstrated mood-stabilizing 
effects [10-14], even though it is unclear if they are as effective as the relatively cheaper 
lithium.  As a result, it would be beneficial to identify factors which predict who may 
respond better than others so treatment with lithium could be targeted to the appropriate 
patients.   
        A growing body of evidence suggests that demographic, clinical [15], and genetic [16] 
factors may play a role in determining the variability in response to lithium treatment.  
There are numerous previous studies of demographic and clinical predictors of lithium 
response, the results of which have been summarized in several recent reviews [17-19].  
There is also evidence from family studies  that genetic factors may be related to response 
as well [20], and several genome-wide association studies (GWAS) have been carried out 
to identify specific associated genetic variants [8, 21, 22].  These studies have typically 
been retrospective or were not specifically designed to examine predictors of response, and 
the results have been inconsistent.  
        To advance our understanding of factors that predict lithium response and contribute 
to the goal of precision medicine for BD, I carried out the following specific aims:  
        Aim 1: To characterize trends in lithium utilization for the treatment of BD in the U.S. 
over the past twenty years.  In this aim, I used data from the National Ambulatory Medical 
Care Survey (NAMCS), a national survey of office-based encounters covering the use of 




prescription of lithium, mood stabilizing anticonvulsants, second generation antipsychotics, 
and antidepressants among patients with BD.  The goal was to gain a better understanding 
of how medication treatment strategies for BD have changed over the past two decades, 
and to confirm the observation that lithium use has been declining in favor of other 
psychotropic medications, despite the fact that lithium is recommended as a first-line 
therapy.   
        Aim 2: To evaluate clinical predictors associated with response to lithium treatment 
over time.  In this aim, I used data from the Pharmacogenetics of Bipolar Disorder (PGBD) 
trial, an eleven site prospective trial of lithium treatment in BD [20] to investigate the 
association of demographic and clinical features with acute and long-term prospective 
response.  The goal is to develop prediction models with clinical variables and test their 
ability to predict response over two years of clinical follow-up in the PGBD trial.  
        Aim 3: To evaluate genetic predictors of lithium response.  In this aim, I first used 
genome-wide SNP genotype data on the PGBD samples, to test lead SNPs that have been 
implicated by prior GWAS of lithium treatment in BD.  Then, I used a novel transcriptome-
wide association (TWAS) approach to evaluate the association of response with specific 
genes and gene sets.  For this, I used RNA-sequencing data on post-mortem brain samples 
from the Lieber Institute for Brain Development to impute into the PGBD samples gene 
expression levels in two brain regions of the limbic system thought to be relevant to BD, 
the amygdala and sub-genual anterior cingulate cortext.  I conducted a TWAS to test if 
imputed expression levels of individual genes (or specific gene sets targeted by lithium) in 
these two brain regions are associated with response to lithium treatment over time.  A 




more closely related to biological mechanisms and it reduces the multiple testing burden.  
Finally, I tested the association of lithium response with polygenic risk scores for several 
related psychiatric disorders that may influence the efficacy of treatment.   
        The overall goal of this project is to advance our understanding of the mechanisms 
underlying the action of lithium and to identify clinical and genetic predictors of lithium 
response among patients with BD.  This work is significant because it will facilitate the 
advent of precision guided treatment for BD by identifying those patients who would most 
benefit from lithium and thereby mitigate the lengthy process of trial and error to find the 





























2.1 Lithium as first-line treatment for bipolar disorder (BD)   
 
        First introduced by John Cade in 1949, the modern use of lithium for treatment of BD 
has been widely studied since.  Findings from these studies have been at times controversial, 
but the evidence for the efficacy of lithium in acute mania and maintenance treatment is 
now well established.  In a meta-analysis of five randomized controlled trials of BD 
patients comparing prophylactic lithium therapy with placebo, lithium was found to be 
more effective than placebo in preventing recurrence of illness, with 60% subjects in the 
lithium group remaining well over a 1-to-2-year period in comparison to 40% in placebo 
[5].  Subsequently, another meta-analysis of six studies of lithium for treating acute mania 
found that 48% of patients responded to lithium compared with 31% in placebo [24].   
        While these seminal reviews unequivocally demonstrate the efficacy of lithium for 




varies widely, with about 30% of treated patients showing only partial response and another 
25% having no response [8], although there are on-going efforts to further define lithium 
response [25].  In addition, lithium use is associated with certain serious side effects 
including reduced urinary concentrating ability, hypothyroidism, and hyperparathyroidism 
[26], requiring careful clinical management due to its narrow therapeutic index [27].  
 
2.2 Other medications for BD treatment  
 
        Lithium’s varying efficacy and side effects have led to the increasing use of other 
medications that also have demonstrated efficacy in BD, including certain anticonvulsants 
and second-generation antipsychotics (SGAs) [10, 11, 28].  Some of the more commonly 
used anticonvulsants for BD include valproic acid/divalproex sodium, lamotrigine,  and 
carbamazepine, while some of the more commonly used SGAs include quetiapine, 
aripiprazole, and risperidone.  However, the long-term effects of newer medications used 
to treat BD are still not clear and anticonvulsants may not necessarily work better than 
lithium in preventing the recurrence of mood episodes or in reducing the overall risk of 
suicide [6, 29].  Furthermore, long-term randomized controlled trials are needed to uphold 
SGAs’ efficacy and ability to improve patients’ psychosocial functioning and quality of 
life [28, 30]. 
        Even though lithium is typically recommended as a first-line therapy for BD, its use 
has been eclipsed in recent years by these other mood-stabilizing anticonvulsants and 
second-generation antipsychotics. This trend has been documented by several recent 




other medications for treatment of BD have been examined through the 1990s and early 
2000s using data from the National Ambulatory Medical Care Survey (NAMCS) and 
Kaiser Permanente, Northern California health system [35-37].  However, there is little 
national level data on trends since 2000.  Data from a single tertiary care clinic at Stanford 
University between 2000 and 2011 suggested a decrease in lithium usage [38].  However, 
it is unclear whether this trend is generalizable beyond the one clinic.  In Chapter 3, I 
examine trends in prescriptions of lithium and other medications for BD in a representative 
sample across the US over a 20-year period from 1996-2015. 
 
2.3 Predictors of clinical response to lithium treatment 
 
        There is continued interest in identifying predictors of response to lithium treatment 
before treatment starts.  The ultimate goal of precision medicine (also referred to as 
individualized or personalized medicine) is to avoid the typical trial and error process of 
finding the right medication for a particular patient during which time the patient might 
continue to experience devastating symptoms and likely be at risk for suicide.  Though the 
promise of precision medicine is increasingly discussed [39], the search for clinical 
predictors of response to lithium treatment actually dates back to the first studies of 
lithium’s prophylactic effect in mood disorders [40].  Indeed, Kleindienst and colleagues 
[17, 18] carried out two comprehensive systematic reviews of predictors of lithium 
response in 2005 in which they identified nearly 2,000 studies published between 1966 and 
2003.  They identified several demographic, psychosocial and clinical predictors that 
appeared to be associated with response, but the results were not always consistent and the 




examined the data from Kleindeinst and colleagues along with new data that has since been 
published and generally re-affirmed the conclusions [19].  Few of the previous studies used 
a prospective designed to investigate predictors of lithium treatment.  In Chapter 4, I 
analyze data from the Pharmacogenetics of Bipolar Disorder (PGBD), one of the first 
prospective trials of lithium monotherapy explicitly designed to identify clinical and 
genetic predictors of lithium response. 
 
2.4 Predictors of genetic response to lithium treatment 
 
        Accumulating evidence suggests that genetics play an important role in differential 
response to lithium treatment among patients with BD.  Genetic characterization can 
potentially aid the stratification of patients with BD, prior to initiation of treatment, into 
those who respond to lithium and those who do not [41].  To date, five GWAS of lithium 
treatment have been carried out [8, 20-22, 42].  The results have been inconsistent, and the 
variants identified confer relatively small increments in risk.  One study tested for 
associations with disease based polygenic risk scores (PRS) [41], which can aggregate the 
contributions of many variants to response, and suggests the potential for more translational 
research involving PRS aimed at personalized prescribing of lithium.  In Chapter 5, I use 
genome-wide SNP genotype data from the PGBD to test lead SNPs and PRS as genetic 
predictors of lithium response in a study that was designed to follow patients on lithium 
monotherapy to better isolate treatment effects specific to lithium.  In addition, I carry out 
a transcription-wide association study (or TWAS), which seeks to identify associations 
with genes by testing variability in genetically determined gene expression [43].  Despite 




features underlying lithium response directly, rather than single nucleotide variants with 
often ambiguous or uncertain annotation and functionality.  This TWAS approach may also 
increase the power over traditional GWAS to identify genetic associations by reducing the 
burden of multiple testing.  The proposed study uses one of the largest available samples 
of post-mortem brains from the Lieber Institute collection to generate more powerful gene 
expression prediction models specifically in brain regions that have been implicated in BD. 
 
2.5 Public health relevance 
 
        The promise of precision medicine is that in the future we will be able to predict 
which treatments or treatment combinations are best suited for specific patients with BD 
so that treatments can be tailored to their individual needs, thus minimizing the process of 
trial and error to find the right medications [45].  This could have tremendous benefit in 
reducing the unnecessary suffering endured by individual patients and minimizing the 
overall burden and costs to public health.  This project aims to characterize the changing 
trends in lithium utilization and to identify the clinical and genetic predictors of lithium 
response that ultimately can be used to bring the promise of precision medicine to a 














Trends in Reports of Lithium and 
Other Medications for Patients with 
Bipolar Disorder in Office-based 




3.1 Abstract  
 
Background 
Studies have shown that rates of lithium use for bipolar disorder in the United States 
declined through the 1990s as other mood stabilizing anticonvulsants and second-
generation antipsychotics (SGAs) became more popular.  We examined recent prescribing 





Twenty years of data from the National Ambulatory Medical Care Survey (NAMCS) were 
used. Weighted percentages of reported use of lithium, anticonvulsants, SGAs and 
antidepressants were calculated over two-year intervals.  Logistic regression was used to 
examine factors related to polytherapy.   
Results 
Reported use of lithium declined from 38.1% (95%CI: 29.8% - 46.3%) in 1996-97 to 14.3% 
(95%CI: 10.6% - 18.1%) in 2006-07 and has remained stable since.  During this time, 
reports of SGAs more than doubled. SGAs and/or anticonvulsants were reported in 75.4% 
(95%CI: 69.5% - 81.3%) of visits with bipolar diagnoses in 2014-15.  Polytherapy 
increased by approximately 3% every two years and in 2014-15 occurred in over 30% of 
visits.  Antidepressants were reported in 40-50% of visits, but their reported use without 
other mood stabilizers decreased from 18.2% (95%CI: 11.7% - 24.8%) in 1998-99 to 7.5% 
(95%CI: 4.2% - 10.9%) in 2014-15.   
Limitations 
The sample had limited power to study the effect of individual medications or the potential 
for differing effects in certain subgroups of patients. 
Conclusions 
This study further documents the declining use of lithium for bipolar disorder, and 
corresponding increase in use of anticonvulsants and SGAs, despite the fact that lithium is 
typically recommended as a first line therapy for bipolar disorder. 
 





        Bipolar disorder is a severe and often disabling psychiatric disorder that affects 
approximately 1-4.4% of the world’s population (Merikangas et al., 2007; Merikangas et 
al., 2011). Bipolar disorder is classically described as having a course of illness that 
alternates between extreme mood states of mania and depression and is characterized by 
episodic relapses along with longstanding disability (Nierenberg et al., 2013). Bipolar 
disorder is a major cause of hospitalizations and health care expenditures, and is also 
associated with an increased risk of suicide (Chesney, Goodwin, & Fazel, 2014). Although 
a number of medications have been approved for treatment of acute episodes or for 
maintenance treatment of bipolar disorder, lithium, the first medication shown to be a mood 
stabilizer in 1949 (Cade, 1949), remains a first line therapy for bipolar disorder (Goodwin 
et al., 2016). However, it is acknowledged that the efficacy of lithium varies widely, with 
about 30% of treated patients fully responding (Alda, 2017), while another 30% show only 
partial response and 25% no response (Hou et al., 2016). In addition, lithium use is 
associated with certain serious side effects (McKnight et al., 2012), requiring careful 
clinical management due to its narrow therapeutic index (Okusa & Crystal, 1994). 
        These factors, along with aggressive marketing by the pharmaceutical industry 
(Nassir Ghaemi, Shirzadi, & Filkowski, 2008), have led to the increasing use of other 
medications that also have demonstrated efficacy in bipolar disorder, including certain 
anticonvulsants, second-generation antipsychotics (SGAs), and antidepressants (Geddes, 
Calabrese, & Goodwin, 2009; Gitlin, 2018; Lindstrom, Lindstrom, Nilsson, & Hoistad, 
2017; Weisler, Cutler, Ballenger, Post, & Ketter, 2006). However, anticonvulsants and 
antipsychotics may be less effective than lithium in preventing the recurrence of mood 




Perriello, & Golden, 2018; Kessing, Sondergard, Kvist, & Andersen, 2005). In addition, 
the appropriate clinical use of antidepressants in bipolar disorder remains uncertain (Gitlin, 
2018; Sachs et al., 2007).  
        There has also been an increase in polytherapy with combinations of the different 
medications. There is some evidence that certain combinations of medications may be 
superior to monotherapy for treating manic episodes, but continued polytherapy after the 
manic phases resolve remains controversial (Geoffroy, Etain, Henry, & Bellivier, 2012). 
In addition, there is inconsistent evidence for treating the depressive episodes with different 
medication combinations in comparison to monotherapy (Lin, Mok, & Yatham, 2006). 
Reports of increased side effects (Brooks et al., 2011) and concerns of potential drug-drug 
interactions (Dunner, 2003) with polytherapy further raise questions about treatment 
choices. 
        The changing trends over time in the use of various medications for treatment of 
bipolar disorder have been documented by several studies in European countries, the results 
from which have suggested a constant or even an increasing trend of lithium use (Bramness, 
Weitoft, & Hallas, 2009; Castells et al., 2006; Hayes et al., 2011; Wilting, Souverein, Nolen, 
Egberts, & Heerdink, 2008). In the US, time trends in prescriptions of lithium and other 
medications for treatment of bipolar disorder have been examined through the 1990s and 
early 2000s using data from the National Ambulatory Medical Care Survey (NAMCS) and 
Kaiser Permanente, Northern California health system (Blanco, Laje, Olfson, Marcus, & 
Pincus, 2002; Hunkeler et al., 2005; Moreno et al., 2007). However, there is little national 




suggested a decrease in lithium usage (Hooshmand et al., 2014); however, it is unclear 
whether this trend is generalizable to other settings. 
        In this study, we examined time trends in prescriptions of lithium and other 
medications for bipolar disorder in a representative sample across the US over a period of 
20 years. We used data from NAMCS, a well-characterized national survey of US office-
based practices of physicians from different specialties, conducted annually across a broad 
range of office settings. Specifically, we examined time trends in prescriptions of lithium, 
mood-stabilizing anticonvulsants, SGAs, and antidepressants in visits with a diagnosis of 
bipolar disorder. The results of our study provide useful data to characterize the changing 
patterns in the management of bipolar disorder in the US over the past two decades. 
 
3.3 Methods  
 
Study Data 
        For the current analysis, we used 20 years of data from the NAMCS between 1996 to 
2015 to summarize and analyze recent time trends in prescriptions of lithium and other 
medications for bipolar disorder. The NAMCS has been conducted annually since 1989 
utilizing a multistage probability design in which a sample of patient visits are randomly 
selected with a pre-specified probability from within certain physician practices, which in 
turn are randomly selected with a pre-specified probability from within primary sampling 
units (PSUs) across the country (CDC, 2015a). Data are obtained on patient, visit, and 




exempt from human subject research, because the data were publicly available and de-
identified. 
        We identified all visits in which the patient had a diagnosis of bipolar disorder as 
indicated by a primary, secondary, or tertiary diagnosis with one of the following ICD-9 
codes: 296.00-296.06, 296.10-296.16, 296.40-296.46, 296.50-296.56, 296.60-296.66, 
296.7, 296.80-296.81, and 296.89. While the number of diagnoses that could be recorded 
per visit increased over the years, we extracted the first three diagnoses for each encounter 
to be consistent across all years. 
        All prescription and non-prescription medications were recorded by physicians for 
each patient visit. Physicians recorded all new medications as well as those patients were 
specifically instructed or expected to continue. All medications were coded using the 
National Drug Code Directory (NDCD) prior to 2006 and the Multum drug dictionary 
starting in 2006 (CDC, 2015b). While the number of medications that could be recorded 
per visit in NAMCS has increased over the years, we extracted the first six medications for 
each encounter to be consistent across all years. 
        We categorized medications taken for bipolar disorder based on their NDCD or 
Multum codes into the following classes: lithium, anticonvulsants used as mood stabilizers 
(valproic acid [divalproex sodium], carbamazepine, and lamotrigine), second-generation 
antipsychotics (SGAs) (aripiprazole, asenapine maleate, clozapine, iloperidone, lurasidone, 
olanzapine, olanzapine/fluoxetine, paliperidone, quetiapine, risperidone, and ziprasidone), 
and antidepressants (amitriptyline, amoxapine, chlordiazepoxide/amitriptyline, citalopram, 
clomipramine, desipramine HCl, duloxetine, escitalopram oxalate, fluvoxamine maleate, 




olanzapine/fluoxetine, paroxetine HCl, paroxetine mesylate, perphenazine/amitriptyline, 
phenelzine sulfate, selegiline, tranylcypromine sulfate, trazodone HCl, and venlafaxine 
HCl). We considered patients as receiving “no medication treatment” for bipolar disorder 
at a visit if they were not reported taking any of the above medications at that visit. 
        Patient characteristics included sex (male versus female), self-reported race 
(Caucasian, African-American, or others), and age (adults versus children, with patients 
under the age of 18 considered as children). The visit type was defined as either “psychiatry” 
if the visit was to a psychiatrist, versus “others” for all other office-based physicians. The 
insurance type used to cover visits was classified as either private insurance, 
Medicaid/Children’s Health Insurance Program (CHIP), Medicare, self-pay, or others. 
 
Data Analysis 
        Visits in which lithium was reported were compared to those in which other or no 
mood stabilizer medications were reported with regard to the patient characteristics, the 
visit type, the insurance type, and antidepressants using contingency tables and chi-square 
tests. Time trends in reports of the different medication classes for bipolar disorder were 
described as weighted percentages calculated from the number of visits in which a 
particular category of medication was reported out of the total number of bipolar disorder 
visits in a given year. We further examined time trends in reports of the different mood 
stabilizer classes within important patient sub-groups, including by bipolar disorder 
subtypes and age, as wells as time trends in reports of the top three most used 
anticonvulsants and SGAs. Next, we used logistic regression to examine the association 




(i.e., lithium, anticonvulsants and/or SGAs). In the logistic regression analyses, we 
included only bipolar disorder visits in which medications from any of the mood stabilizer 
classes were reported. All analyses were adjusted for visit weights, clustering, and 
stratification of data using design elements provided by the National Center for Health 
Statistics that allow generalization of the NAMCS data to the US population. In order to 
obtain more stable estimates of the frequency of drug reports, we combined visit data over 





        Between 1996 and 2015, the NAMCS included data on 645,784 visits to office-based 
physicians; of these, 5,400 (0.6%) visits involved patients who had a bipolar disorder 
diagnosis, including approximately 47% with bipolar I disorder, 13% with bipolar II 
disorder, and 40% with bipolar disorder not otherwise specified. Table 1 summarizes the 
characteristics of these bipolar disorder visits and compares them by whether lithium, other 
mood stabilizers (anticonvulsants and/or SGAs), or no mood stabilizers were reported. The 
majority of visits involved Caucasian adults, and just over 60% were with females. Over 
three-quarters of the visits were with psychiatrists, and over 40% were covered by private 
insurance, while another 35% were covered by Medicare and/or Medicaid. Lithium was 
reported in approximately 17% of bipolar disorder visits, other mood stabilizers 
(anticonvulsants and/or SGAs) were reported in 52%, and no mood stabilizers were 
reported in 31%. There were significant differences in race, age, visit type, insurance type, 




Reports of any mood stabilizers were more likely to occur at psychiatry visits. Reports of 
lithium were more likely to involve Caucasian adult patients who were self-paying and not 
on Medicaid. Compared to lithium, reports of other mood stabilizers were more likely 
among children and to be accompanied with reports of antidepressants.  
 
Time Trends in Mood Stabilizer Classes 
        The percentage of bipolar disorder visits among all visits steadily increased over the 
study period from 0.3% (95% CI: 0.2% - 0.4%) in 1996-97 to 0.8% (95% CI: 0.6% - 1.0%) 
in 2014-15. Among the bipolar disorder visits, the percentage in which any mood stabilizer 
was reported remained stable at approximately 70%, until 2014-15, when there was an 
increase to 79.4% (95% CI: 73.9% - 85.0%). However, during this period there was a 
consistent decline in reports of lithium (Figure 1). The percentage decreased from 38.1% 
(95% CI: 29.8% - 46.3%) in 1996-97 to 14.3% (95% CI: 10.6% - 18.1%) in 2006-07, and 
it remained steady at approximately 14% from 2008-09 on. During this period, there was 
a parallel increase in reports of SGAs, which more than doubled from 19.2% (95% CI: 
12.4% - 26.0%) in 1996-97 to 48.0% (95% CI: 42.2% - 53.9%) in 2008-09 and reached a 
peak of 52.2% (95% CI: 43.9% - 60.5%) in 2014-15. Reports of anticonvulsants for bipolar 
disorder remained generally stable at around 40%, with a low of 31.0% (95% CI: 23.9% - 
38.1%) in 1996-97 and a recent peak of 43.3% (95% CI: 36.9% - 49.7%) in 2014-15. 
Overall, by 2014-15, other mood stabilizers (anticonvulsants and/or SGAs) were reported 
in 75.4% (95% CI: 69.5% - 81.3%) of bipolar disorder visits. 
 




        Trends over time in reports of different mood stabilizer classes were generally similar 
for patients with different bipolar disorder subtypes, except for a somewhat greater overall 
reports of lithium for bipolar I disorder compared to other bipolar diagnoses 
(Supplementary Figure 1). By the end of 2014-15, lithium was reported for 19.5% (95% 
CI: 11.0% - 27.9%) of visits for patients with bipolar I disorder compared to only 11.6% 
(95% CI: 7.0% - 16.2%) of visits for patients with other bipolar diagnoses.   
        Trends over time in reports of the different classes of mood stabilizers were also 
generally similar when comparing adults with children (age < 18 years old), except for two 
noteworthy differences. First there was greater variability in estimates over time for 
children due to the smaller sample size, and second, there was a notable difference in SGAs 
reports (Supplementary Figure 2). The decline in reports of SGAs seen after 2008-09 
occurred in both adults and children, but was more precipitous in children, where reports 
of SGAs dropped from a high of 70.9% (95% CI: 55.0% - 86.7%) in 2008-09 to 43.2% 
(95% CI: 26.1% - 60.3%) in 2012-13. However, reports of SGAs in children rebounded in 
2014-15 to a high of 78.4% (95% CI: 50.2% - 100%), although given the wide confidence 
intervals, it is unclear if this reflects a genuine change or is due to unstable estimates from 
a small sample size. 
 
Time Trends in Specific Anticonvulsants and SGAs 
        Trends over time in reports of the top three most prescribed anticonvulsants and SGAs 
between 1996-2015 are shown in Figure 2. Among anticonvulsants, there was a notable 
decline in reports of valproic acid/divalproex sodium coupled with an increase in 




acid/divalproex sodium peaked in 1998-99 at almost 35%, but then declined to around 14% 
in 2014-15. Conversely, as of 2006-07 lamotrigine became the most widely reported 
anticonvulsant and was reported in approximately 28% of bipolar disorder visits in 2014-
15. Among SGAs, there was a steady increase in the percentage of bipolar disorder visits 
with reports of quetiapine and aripiprazole since their introduction. Beginning in 2004-05, 
quetiapine became the most widely reported SGA, being reported in 22.0% (95% CI: 15.3% 
- 28.7%) of bipolar disorder visits in 2014-15. Since 2008-09, aripiprazole has been the 
second most widely reported SGA and was reported in 12.3% (95% CI: 7.4% - 17.2%) of 
bipolar disorder visits in 2014-15. 
 
Time Trends in Polytherapy 
        The use of multiple medications to treat mood in bipolar disorder has steadily 
increased since 1996-97. In 1996-97, two or more mood stabilizers were reported in only 
20.0% (95% CI: 13.1% - 26.8%) of bipolar disorder visits; however, by 2014-15 the 
percentage had gone up to 33.6% (95% CI: 24.8% - 42.4%) (Figure 3). Among bipolar 
disorder visits in which any mood stabilizer treatment was reported, the odds of 
polytherapy with mood stabilizers increased by 1.03 times (95% CI: 0.98 - 1.08) every two 
years, after controlling for sex, race, age, visit type, and insurance type. Of these other 
covariates, the provider type was significantly associated with increased polytherapy, the 
odds being 3.16 (95% CI: 2.12 - 4.71) times greater in psychiatric versus non-psychiatric 
visits. 
        Despite the general increase in polytherapy of mood stabilizers over the past two 




from a high of 13.8% (95% CI: 8.6% - 19.0%) in 1996-97 to 10.7% (95% CI: 6.5% - 15.0%) 
in 2014-15. Over this same time, reports of lithium monotherapy decreased even more 
dramatically from 24.3% (95% CI: 18.0% - 30.6%) in 1996-97 to only 4.0% of bipolar 
disorder visits (95% CI: 2.3% - 5.7%) in 2014-15. 
 
Time Trends in Antidepressants 
        Antidepressants were consistently reported in approximately 40-50% of bipolar 
disorder visits (Figure 4). Moreover, the percentage of visits in which antidepressants were 
reported by themselves without any mood stabilizers decreased from 18.2% (95% CI: 11.7% 
- 24.8%) in 1998-99 to 7.5% (95% CI: 4.2% - 10.9%) in 2014-15. At the same time, the 
percentage of visits in which antidepressants were reported with mood stabilizer(s) steadily 
increased from 26.3% (95% CI: 20.2% - 32.3%) in 1996-97 to 45.3% (95% CI: 38.1% - 
52.6%) in 2014-15. Reports of antidepressants were generally lower in children 
(Supplementary Figure 2), ranging from 20-40% for most of the past two decades, 
compared to 40-50% in adults. However, in 2014-15, the percentage notably increased in 
children to the same level as adults, reaching above 50% for both.  
  
3.5 Discussion  
 
        Lithium, the first medication identified to be effective for treating bipolar disorder, 
remains a first line therapy (Severus, Schaaff, & Moller, 2012). However, the use of lithium 
has been steadily declining over the past thirty years. The results reported in this paper 
further document the decline in reports of lithium use to approximately 15% of physician 




reported use of mood stabilizing anticonvulsants, initially valproic acid, followed by 
lamotrigine, and more recently the SGAs, particularly quetiapine and aripiprazole. Mood 
stabilizing anticonvulsants and SGAs are each now reported in approximately 40-50% of 
bipolar disorder visits, and they are concomitantly reported in over 20% of these visits. 
Moreover, we found that polytherapy with mood stabilizing treatments for bipolar disorder 
has steadily increased since 1998-99, such that two or more of any mood stabilizer 
medications are now reported in over 30% of bipolar disorder visits. By contrast, reports 
of lithium monotherapy have steadily declined over this time period to approximately 4% 
of bipolar disorder visits. 
        The current findings are consistent with those from previous studies in the US. An 
earlier analysis of the NAMCS data using only outpatient psychiatrist visits found that 
prescriptions of lithium declined from 50.9% (95%CI: 47.0% - 54.8%) in 1992-95 to 30.1% 
(95%CI: 26.5% - 33.7%) in 1996-99 (Blanco et al., 2002). Our findings extend this 
observation into the first two decades of the 2000’s. In addition, a smaller study of patients 
referred to a tertiary care referral clinic found that lamotrigine, quetiapine, and aripiprazole 
use more than doubled from 2000-05 to 2006-11, while lithium, valproate, olanzapine and 
risperidone use decreased (Hooshmand et al., 2014). Our results show similar time trends 
at the national level. 
        Studies of time trends in lithium use have been conducted in several different 
international countries as well. These include studies from Spain using annual lithium 
purchase data between 1985-2003 from the ECOM database of the Spanish Ministry of 
Health (Castells et al., 2006); the Netherlands using outpatient data between 1996-2005 




Souverein, Nolen, Egberts, & Heerdink, 2008); Scandanavia using prescription data 
between 2005-06 from three Sweden, Norway and Denmark prescription databases 
(Bramness, Weitoft, & Hallas, 2009); and the United Kingdom using primary care data 
between 1995-2009 from the Health Improvement Network (THIN) (Hayes et al., 2011). 
Interestingly, studies from¬¬ these other countries have suggested a constant, or even 
increasing, rate of lithium use. For example, the UK study reported the proportion time in 
treatment with lithium remained constant around 30% across 1995-2009 (Hayes et al., 
2011). Many of these studies, however, covered either an earlier (all before 2009) or a 
shorter time frame than the current study, which might partly explain the differences 
observed with our findings. 
        Our study used data from a nationally representative sample of office based clinical 
visits across the US. In addition, these data covered a twenty-year period from 1996-2015 
and were collected using largely consistent procedures. This allowed us to have a relatively 
large sample to make statistical inferences, which is an advantage over past bipolar disorder 
studies. By combining the data into two-year intervals, we attempted to obtain more stable 
results while not losing the ability to observe time trends. Nevertheless, the study sample 
may not have been sufficiently large to detect time trends in subgroups of patients or time 
trends specific to individual medications. In addition, the study relied on physician 
assigned diagnoses that were not validated, which raises the possibility of diagnosis errors. 
This might be especially problematic because of the high rate of mis-diagnoses for bipolar 
disorder (Ruggero, Zimmerman, Chelminski, & Young, 2010). Indeed, we observed an 
unusually high rate of bipolar disorder not otherwise specified, which may reflect some of 




disorder and its sub-types, the rates of reported medication use may be mis-leading. 
Furthermore, the dataset does not distinguish patients with bipolar disorder that may be in 
different mood states. As a result, we were unable to determine whether the different 
medications were being taken for mania, depression, or maintenance. Finally, we did not 
have any information on adherence, so we can only comment on what medications patients 
were supposed to be taking. 
        Despite these limitations, the declining use of lithium that we observed in the US is 
striking. It is also interesting to note that the use of lithium is reported less frequently 
among African Americans and for patients on Medicaid, which may reflect disparities in 
access to health care (Akinhanmi et al., 2018). Lithium has been shown to be an effective 
treatment for bipolar disorder, and it is typically recommended among first-line treatments 
for bipolar disorder, including in the manic, depressive and maintenance phases (Yatham 
et al., 2018). Despite this, there was a notable increase in the reported use of alternative 
mood stabilizers, including anticonvulsants and SGAs, at the apparent expense of lithium. 
However, there is limited evidence regarding the comparative safety and effectiveness of 
these medications. The increasing polytherapy with mood stabilizers that we observed has 
also been documented in bipolar disorder samples from other countries and in psychiatry 
visits overall (Hayes et al., 2011; Mojtabai & Olfson, 2010). This is of interest because 
there may be even less empirical evidence to guide which combinations of mood stabilizers 
are most effective despite increased risk for side effects (Brooks et al., 2011). On the 
encouraging side, we did observe a decline in the reported use of antidepressants without 
mood stabilizers, which is consistent with guidelines to avoid antidepressant monotherapy 




help guide which of the treatment options will work best for different patients with bipolar 
disorder, further research is needed to achieve the promise of precision medicine to better 
predict which medications or medication combinations are most effective for individual 
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Sex, (%)     0.15 
Female  61.6 58.8 62.0 62.5  
Male  38.4 41.2 38.0 37.5  
Race, (%)     <0.0001v, vi 
Caucasian  88.1 91.5 86.9 88.9  
African-American  7.9 3.7 8.8 8.2  
Others   4.0 4.8 4.3 2.9  
Age, (%)     <0.0001v, vii 
Adults (>=18 years) 91.6 94.4 89.3 93.8  
Children 8.4 5.6 10.7 6.2  
Visit Type, (%)     <0.0001vi, vii 
Psychiatry 76.8 83.0 83.5 62.3  
Others  23.2 17.0 16.5 37.7  
Insurance Type, (%)     <0.0001v, vi 
Private Insurance 43.9 43.9 44.7 42.7  
Medicaid, CHIP 17.3 11.8 19.0 17.5  
Medicare 17.6 19.3 16.2 19.0  
Self-pay 13.6 16.6 13.0 13.1  
Others 7.6 8.3 7.2 7.8  
Antidepressants, (%)     <0.0001v, vii 
Yes 46.9 42.3 54.1 38.4  
No 53.1 57.7 45.9 61.6  
i All numbers shown in the table are weighted percentages (see Methods). 
ii Among visits being prescribe lithium, 450 were prescribed lithium monotherapy (as the only mood 
stabilizer), 129 were concomitantly prescribed anticonvulsants (but no SGAs), 243 SGAs (but no 
anticonvulsants), and 103 both.   
iii Among visits being prescribed non-lithium mood stabilizers, 1,003 were prescribed anticonvulsants as the 
only mood stabilizers, and 1,094 SGAs.  685 were concomitantly prescribed anticonvulsants and SGAs.   
iv P-values are from Chi-squared tests comparing percentages across the three treatment groups. 
v Chi-squared tests p<0.017 (0.05/3) comparing Lithium vs Other Mood Stabilizers 
vi Chi-squared tests p<0.017 (0.05/3) comparing Lithium vs No Mood Stabilizers 










  Figure 1. Trends between 1996-2015 in the percentage of visits in which different 
categories of mood stabilizer medications were reported bipolar disorder. Shown are 
percentages among visits with a diagnosis of bipolar disorder. Error bars show 95% 








Figure 2. Trends between 1996-2015 in the percentage of visits in which specific (A) 
anticonvulsants and (B) SGAs were reported. Aripiprazole entered the US market 
later than 1996, which explains why aripiprazole first appears in the NAMCS data in 
2004-05. Shown are percentages among visits with a diagnosis of bipolar disorder. 








  Figure 3. Trends between 1996-2015 in percentage of visits in which monotherapy 
vs polytherapy of mood stabilizer medications was reported. Mood stabilizers refer 
to lithium, anticonvulsants, or second-generation antipsychotics; monotherapy 
means taking only one of these medications for bipolar disorder, while polytherapy 
means taking any combination of more than one of these medications. Shown are 
percentages among visits with a diagnosis of bipolar disorder. Error bars show 95% 









Figure 4. Trends between 1996-2015 in percentage of visits in which antidepressants 
were reported. Shown are percentages among visits with a diagnosis of bipolar 
disorder. Error bars show 95% confidence intervals for each weighted estimate of the 









  Supplemental Figure 1. Trends between 1996-2015 in percentage of visits in which 
different categories of medications were reported by bipolar disorder sub-type, (A) 
bipolar I disorder vs (B) other bipolar disorders. Shown are percentages among visits 
with a diagnosis of bipolar disorder. Error bars are not shown due to smaller sample 










Supplemental Figure 2. Trends between 1996-2015 in percentage of visits in which 
different categories of medications were reported for (A) adults vs (B) children. 
Shown are percentages among visits with a diagnosis of bipolar disorder. Error bars 

















Clinical Predictors of Response to 
Lithium Treatment in The 
Pharmacogenomics of Bipolar 
Disorder (PGBD) Study 
 
 
4.1 Abstract  
 
Background 
Lithium is regarded as a first line treatment for bipolar disorder (BD), but partial response 
and non-response commonly occurs.  There exists a need to identify lithium non-
responders prior to initiating treatment.  The Pharmacogenomics of Bipolar Disorder 





The PGBD Study was an eleven-site prospective trial of lithium treatment in bipolar 1 
disorder.  Subjects were stabilized on lithium monotherapy over four months and gradually 
discontinued from all other psychotropic medications.  After ensuring a sustained clinical 
remission (defined by a score of <3 on the CGI for four weeks) had been achieved, subjects 
were followed for up to two years to monitor clinical response. Cox proportional hazard 
models were used to examine the relationship between clinical measures and time until 
failure to remit or relapse.  
Results 
A total of 345 individuals were enrolled into the study and included in the analysis.  Of 
these, 101 subjects failed to remit or relapsed, 88 achieved remission and continued to 
study completion, and 156 were terminated from the study for other reasons.  Significant 
clinical predictors of treatment failure (p<0.05) included baseline anxiety symptoms, 
functional impairments, negative life events and lifetime clinical features such as a history 
of migraine, suicidal ideation/attempts, and mixed episodes, as well as a chronic course of 
illness.   
Conclusions 
In this PGBD Study of lithium response, several clinical features were found to be 
associated with failure to respond to lithium.  Future validation is needed to confirm these 
clinical and genetic predictors of treatment failure and their use clinically to distinguish 
who will do well on lithium before starting therapy. 
 





        Lithium is regarded as a first-line treatment for bipolar disorder (BD) (1-3), but it does 
not work for all patients.  The modern use of lithium for treatment of BD was first 
introduced by John Cade in 1949, and it has been widely studied since. Although findings 
from these studies have been controversial, the evidence for the efficacy of lithium in acute 
mania and maintenance treatment is well established.  In a meta-analysis of five 
randomized controlled trials of BD comparing prophylactic lithium therapy with placebo, 
Geddes and colleagues (4) found that lithium is more effective than placebo in preventing 
recurrence of illness, with 60% in the lithium group remaining well over 1–2 years 
compared with 40% in the placebo group.  In a subsequent meta-analysis of six studies of 
lithium in the treatment of acute mania, Yildiz and colleagues found that 48% of patients 
responded to lithium compared to 31% for placebo (5). While these seminal reviews 
unequivocally demonstrate the efficacy of lithium for both acute mania and maintenance 
treatment of BD, they also highlight that anywhere from 40-50% of patients do not respond 
adequately over a two year period and require either the addition of or a change to another 
psychotropic drug (5).  These findings are consistent with observational data from 
longitudinal cohort studies (6-8). 
        There is considerable continued interest in identifying predictors of response to 
lithium before starting treatment in order to avoid the typical trial and error process of 
finding the right medication for a particular patient during which time he or she may 
continue to experience devastating symptoms and be at risk for suicide.  This is the goal of 
precision medicine.  Although the promise of precision medicine has garnered a great deal 
of attention recently (9), the search for predictors of lithium response dates back to the very 




on socio-demographic or clinical correlates of response, but there is increasing effort to 
identify relevant biological markers, including biomarkers from neuroimaging, 
neurophysiology or molecular studies.  The evidence from these studies to date is largely 
conflicting. 
        The Pharmacogenomics of Bipolar Disorder (PGBD) Study (www.clinicaltrials.gov, 
NCT01272531) is one of the first prospective studies of lithium treatment designed to 
prospectively identify clinical and molecular predictors of lithium response.  We report 
here the results of an analysis of data from this study to examine clinical predictors. 
 
4.3 Methods  
 
Study Overview 
        The PGBD was one of fourteen research projects in the Pharmacogenetic Research 
Network funded by the National Institute of Health to support multi-disciplinary, 
collaborative research on how genetic factors contribute to inter-individual differences in 
responses to medications.  The PGBD set out to conduct a multi-site prospective study of 
lithium monotherapy in the treatment of BD.   
        The details of the trial have been described elsewhere (11).  Briefly, the goal of the 
study was prevention of illness recurrence by lithium monotherapy.  All patients were 
observed in an observation phase lasting 4 weeks to confirm they were in remission defined 
by having a Clinical Global Impression of Severity Scale (CGI-S) score of <3 (mildly ill) 
for at least 4 weeks.  After the observation phase, the patients entered a two-year 
maintenance phase, during which they were assessed every 2 months to monitor their on-




lithium monotherapy were first transitioned to lithium monotherapy in a stabilization phase 
that lasted a maximum of 16 weeks which included visits every other week for the first 8 
weeks and one visit per month for the next two months.  Throughout the follow-up, patients 
were allowed to take a benzodiazepine for anxiety and/or zolpidem for sleep.  For 
investigation of genetic and other molecular predictors of response to lithium treatment, 
blood was collected from all patients and a skin biopsy on a subset of patients.  A range of 
clinical measures (described below) was collected at the screening and subsequent visits to 
monitor clinical progress and enable investigation of clinical predictors of response.   
 
Participants 
        Patients were enrolled into the study at nine sites within the United States and two 
international sites.  The nine domestic sites included: University of California, San Diego; 
Indiana University; University of Chicago; University of Pennsylvania; University of Iowa; 
Johns Hopkins University; Case Western Reserve University; University of Michigan; and 
the Mayo Clinic.  The two international sites were University of Bergen, Norway, and 
Dalhousie University in Halifax, Canada.  
        Patients were included in the study if they:  1) had bipolar I disorder in any phase of 
illness; 2) were naïve to or not presently on lithium and had at least one affective episode 
meeting DSM-IV criteria in the last 12 months or were currently on lithium and did not 
have any history of mood episodes meeting DSM-IV criteria in the last 6 months; 3) were 
able to give informed consent; 4) were 18 years or older; and 5) were currently 
symptomatic, as defined as a CGI-S score of at least 3 (mild severity), unless the patient 




were included if they agreed to use adequate contraception and inform their doctor at the 
earliest possible time of their plans to conceive.   
        Patients were excluded if they: 1) were unwilling or unable to comply with study 
requirements;  2) had renal impairment (serum creatinine >1.5 mg/dL);  3) had thyroid 
stimulating hormone (TSH) over >20% above the upper normal limit or, if on thyroid 
medication, had not been euthyroid for at least 3 months before the first visit; 4) were 
currently in crisis such that inpatient hospitalization or other crisis management should take 
priority; 6) met criteria for physical dependence requiring acute detoxification from alcohol, 
opiates or barbiturates; 7) were pregnant or breastfeeding; 8) had participated in a clinical 
trial of an investigational drug within the past 1 month, or 9) had a history of lithium 
toxicity, not due to mismanagement or overdose, that required treatment. 
        All study procedures were approved by local Institutional Review Boards (IRBs), and 
all patients provided informed consent.  This analysis included data on the first 345 BD 
patients who enrolled into the study and completed at least four weeks of the study.   
 
Clinical Outcomes 
        Patients were followed until they:  1) completed all study visits over two years of the 
maintenance phase (or had achieved the maintenance phase and were still active in the on-
going study by the date of the data freeze), 2) were terminated from the study before 
completion of all visits because of failure to achieve (i.e., failure to remit) or maintain (i.e. 
relapse) stabilization on lithium, or 3) were terminated from the study for other reasons.      
        Failure to remit was defined by the inability to achieve clinically sustained remission 




or based on clinical judgment that the patient was unable to adequately stabilize on lithium 
monotherapy.   
        Relapse was evaluated using the Mood Episode Checklist which summarizes DSM-
IV criteria for mania and depression and was collected at each visit during the maintenance 
phase. Relapse was defined by the following:  1) meets criteria for mania and has a CGI-S 
of 5 (markedly ill) or greater; 2) meets criteria for a major depressive episode with 4 week 
duration; 3) meets criteria for a mixed episode with CGI-S of 5 or greater; 4) psychiatric 
hospitalization for a mood episode is required; or 5) in the physician’s judgment the patient 
cannot be managed on monotherapy and a change in medication is required. Episodes of 
hypomania without impairment of function were not considered relapses. These criteria 
were designed to be stringent so as to detect clear failures of prophylaxis, rather than brief 
episodes that might not require a medication change in clinical practice.  
 
Clinical Predictors 
        Patients were evaluated with the Diagnostic Interview for Genetic Studies (DIGS) in 
order to establish a diagnosis of bipolar I disorder by DSM-IV criteria and collect detailed 
historical clinical information about current and lifetime mental illnesses.  Patients also 
completed a range of self and clinician rated scales at the screening and subsequent visits 
to document the clinical course of illness and factors that may relate to the course.  Self-
rated scales included The Childhood Life Events Scale; The Lifetime History of 
Aggression Scale; The Columbia Suicide Symptom Severity Scale; The Basic Language 
Morningness Scale (BALM); the Temperament Evaluation of Memphis, Pisa, Paris and 




Depression Symptomatology Self-Report (QIDS-SR-16); the Sheehan Disability Scale; the 
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q); and the Life Events 
Questionnaire (LEQ). Clinician rated scales included the following:  the Clinical Global 
Impressions of Severity Scale (CGI-S); the Hamilton Rating Scale for Anxiety (HAM-A); 
the Montgomery Asberg Depression Rating Scale (MADRS); the Clinician Administered 
Rating for Mania (CARS-M); and the Modified Scale for Suicidal Ideation (MSSI).  From 
the assessments collected either at the screening or baseline visits, we derived 43 clinical 
variables for analysis that were selected based on clinical experience and an expert review 
of the literature involving three of us (JK, MA, and JC).  These included variables on socio-
demographic factors, baseline symptoms, clinical history and course, co-morbid illnesses, 
family history of mental illness, childhood and current life events, and level of functioning.  
See Table 1 for a full list of variables that were examined. 
 
Statistical Analyses 
 Differences in socio-demographic factors between patients who completed all 
study procedures, those who failed to remit or experienced a relapse, and those who were 
terminated from the study for other reasons were compared using chi-square tests for 
categorical variables and one-way ANOVA for continuous variables.  We then used 
survival analysis with Cox Proportional Hazard models to examine the relationship 
between clinical predictors measured at baseline and the time from study entry to treatment 
failure, which was defined as the time of the last visit at which the patient was determined 
to have failed to remit or to have relapsed.  All other patients were censored at the time of 




models that additionally controlled for potential confounders including age at study entry, 
sex, race, and lithium status upon entry into the study.  These variables were selected from 
the available data because they are important socio-demographic factors that experience 
indicated may be relevant and/or they were found to differ with treatment outcome.  Race 
was captured as a categorical variable for Caucasians, Asians, African Americans, or other.  
Lithium status upon entry into the study was captured as a categorical variable to 
distinguish those who entered the study stable on lithium monotherapy, on lithium plus 
other psychotropic medications, or not on lithium.  We used two-tailed p<0.05 to declare 
associations statistically significant. We did not correct for multiple testing for two reasons: 
the clinical predictors were carefully selected based on prior hypotheses that they may be 
relevant to treatment response, and we reasoned Bonferroni correction would be too 
conservative and we wanted to prioritize detection of true associations over rejection of 
false positives.         
        To determine if the associations with treatment response of the clinical predictors 
identified through the above procedures differ in the initial versus later phases of follow-
up, we stratified the survival analyses and looked first at survival over the stabilization and 
observation phases among all patients who entered the study, and then separately over the 
maintenance phase among patients who entered the maintenance phase.  To formally test 
for differences in association, we combined the stratified survival data and included in the 
Cox Proportional Hazard models an interaction term between the clinical predictor and an 
indicator variable for the stabilization/observation versus maintenance phases. 
        To assess the robustness of observed associations to the assumptions of the survival 




response variables for analysis: 1) an acute response variable based on whether patients 
proceeded to the maintenance phase or not; and 2) a prophylactic response variable which 
contrasted patients who completed all study visits or who had reached the maintenance 
phase and were still active on study as of the data freeze versus those who failed to remit 
or who relapsed on lithium monotherapy before completing all study visits.  We then used 
logistic regression to examine the association between the clinical predictors and the two 
different dichotomous response variables in models that controlled for the same potential 
confounders as in the survival analysis.  The inferences drawn from these two alternative 
logistic regression analyses were nearly identical to those from the survival analysis, so we 
report here only the results from the survival analysis.  All analyses were performed 
independently at two study sites to ensure the accuracy of the results. 
        Finally, to evaluate the predictive ability of a model that included all clinical 
predictors individually found to be significantly associated with treatment failure, we 
carried out a receiver-operating curve (ROC) analysis specifically for survival data. We 
first carried out multiple imputation to fill in missing covariate data and maximize the 
available data for the ROC analysis.  Multiple imputation was performed on the predictor 
dataset with the mi command in STATA to generate 35 imputed datasets.  A consensus 
imputed dataset was generated by taking the median (for continuous covariates) or modal 
(for categorical covariates) values across the 35 imputed datasets.  We note that this 
procedure does not take into account the uncertainty in the consensus imputed estimates, 
but we reasoned it would be sufficient for obtaining reasonable estimates from the ROC 
analysis.  After confirming that analyses with the consensus imputed dataset yielded results 




compare the ROC curves of nested models, including a base model that included the base 
variables controlled for in all analyses (age at study entry, sex, race, and lithium status upon 
entry into the study) and a full model that included the base variables plus all clinical 
predictors that were individually associated with treatment failure (see Table 3).  The 
consensus imputed dataset was randomly split into ten non-overlapping subsets of 
approximately equal size, with approximately the same proportion of censored and event 
observations across all subsets. Cox models for all four models were then fit using nine out 
of ten subsets, leaving the tenth subset as a hold-out set. Using the results of the fitted 
models, linear predictor scores were obtained for observations in the hold-out set. Model 
fitting and prediction were repeated ten times, where a different subset of data was held 
out each time. Predicted survival ROC curves over two years were estimated for the linear 
predictions using the CoxWeights function from the risksetROC R package (12,13). The 
area under the curve (AUC) for the ROC of the four models were generated, and the 
differences in AUC among the four were recorded. This process was repeated across 
10,000 permutations of survival status and time of censoring pairings. The p-value for AUC 
difference was derived as the proportion of permuted AUC differences that were greater 
than the unpermuted AUC difference.     
 
4.4 Results  
 
        Figure 1 shows a CONSORT like flow diagram of the study.  A total of 345 
individuals were enrolled into the study and included in the analysis.  Of these, a total of 
194 patients successfully advanced to the maintenance phase, while 60 patients failed to 




patients were terminated from the study for other reasons prior to the maintenance phase. 
Of the 194 patients who entered the maintenance phase, 41 experienced a relapse, 65 were 
terminated for other reasons, and 88 completed the study or were still in active treatment 
as of the date of data freeze. 
        Table 2 shows basic socio-demographic characteristics of the study sample broken 
down by the final outcome status of the patients, whether they completed the study (or 
were stabilized in maintenance and still active on the study), experienced a treatment 
failure, or were terminated for other reasons.  There were no significant differences in age, 
sex or race between these three broad outcomes.  Patients who entered the study stable on 
lithium monotherapy were significantly more likely to complete the study compared with 
those who either were on lithium and other psychotropic medications or were not on 
lithium on study entry.  There were also significant differences between the sites in the 
outcomes achieved by the patients.  These differences were largely explained by the 
proportion of patients at each site that entered the study stable on lithium, highlighting the 
importance of controlling for this potential confounder in subsequent analyses. 
        We then examined the association between hypothesized clinical predictors of lithium 
response and treatment response.  Table 1 shows the list of clinical predictors that were 
selected a priori for investigation and the self and clinician rated scales from which they 
were derived.  We examined each predictor individually in survival models controlling for 
factors that we reasoned may confound the relationship with treatment response because 
they are important socio-demographic factors or were found to differ with outcome status, 




3 shows the results for those clinical predictors that were significantly associated with 
treatment response at nominal significance of p<0.05.   
        The significant clinical predictors fell into four main categories: baseline anxiety 
symptoms, lifetime clinical features, daily functioning, and life events.  The severity of 
anxiety symptoms at baseline as measured by total score on the HAM-A was significantly 
associated with increased risk of treatment failure when examined as a continuous 
covariate (hazard ratio [HR] 1.05, 95% confidence interval [CI] 1.03 to 1.08) and 
categorically as none, mild, moderate and severe (results not shown).  Interestingly, a pre-
existing diagnosis of co-morbid anxiety disorder meeting DSM-IV criteria was not 
associated with treatment response, suggesting that baseline symptoms rather than lifetime 
diagnosis are more relevant.  The lifetime clinical features that positively associated with 
increased risk of treatment failure included a history of migraine (HR 1.62, 95% CI 1.03 
to 2.55), suicidal behavior (with an apparent dose-response relationship of HR 1.65, 95% 
CI 0.95 to 2.86 for ideation and HR 2.03, 95% CI 1.16 to 3.53 for more serious attempts) 
and history of mixed episodes (HR 1.60, 95% CI 1.01 to 2.53), as well as a chronic (non-
episodic) pre-treatment course of illness (HR 2.92, 95% CI 1.76 to 4.83).  Overall, 
functional disability related to illness was also an important predictor of treatment failure 
as assessed by the clinician with regard to lifetime disability (HR 1.80, 95% CI 1.13 to 
2.86) and self-rated current disability on the Sheehan Disability Scale completed at baseline 
(HR 1.06, 95% CI 1.03 to 1.08).  The self-rated current disability measure encompassed 
functional impairment in work, family and social life, all of which were found to be 
significantly associated with treatment failure, but for simplicity only results of total 




(HR 1.97, 95% CI 1.28 to 3.03) or recent negative life events (HR 1.02, 95% CI 1.00 to 
1.03) as captured by the Childhood Life Events scale or the Lifetime Events Questionnaire, 
respectively, were also associated with increased risk of treatment failure.  Stratification of 
the survival analyses by study phase (Supplemental Table 1) showed that the association 
of these clinical predictors with treatment failure did not significantly differ between the 
stabilization/observation versus maintenance phases (all interaction P > 0.05).         
        To evaluate how well a model that included the significant clinical predictors could 
predict lithium treatment failure over a two-year period, we carried out an additional ROC 
analysis (Figure 2).  The ROC curve for a full model with all significant clinical predictors 
plus the base variables had an AUC of 0.74, which was significantly different from the null 
(p=0.0001).  This was better than the base model that included only the base variables, 
which had an AUC of 0.68, although the difference was not significantly different (p=0.13). 
 
4.5 Discussion  
 
        We report here the first results from the PGBD Study, in which we examine clinical 
predictors of response to lithium treatment for bipolar disorder (BD).  Lithium is a first line 
treatment for BD and can be remarkably effective in controlling the devastating symptoms 
of BD.  However, it is not effective in everyone and anywhere between 40-50% of patients, 
or even more depending upon the length of follow-up, may need to switch therapeutic 
regimens.  We identified several clinical markers that are associated with failure to respond 
to lithium treatment.  These include current anxiety symptoms, functional impairments, 




suicidal ideation/attempts, and mixed episodes, as well as co-morbid personality disorder 
and a chronic course of illness.  Future validation will be required to confirm whether these 
clinical markers are associated with treatment failure and whether they can be used 
clinically to effectively distinguish who will and will not do well on lithium before starting 
therapy.  The particular significance of the present study is that it represents a prospective 
clinical evaluation of lithium response, in contrast to the extensive literature evaluating 
lithium response retrospectively.  
        There is a long history of searching for clinical predictors of response to lithium 
treatment that can help guide treatment decisions.  In 2005, Kleindienst and colleagues 
(14,15) carried out two comprehensive systematic reviews of predictors of lithium response 
in which they identified nearly 2,000 studies published between 1966 and 2003 on this 
topic.  In one review, they focused on studies that examined psychosocial and demographic 
predictors, and identified nine that emerged as consistently associated with lithium 
response.  Four were associated with good response (high social status, social support, good 
compliance, and “dominance” personality trait), while five were associated with poorer 
response (stress, high expressed emotion, neurotic personality trait, unemployment, and 
high number of life events).  In the other review, they focused on studies that examined 
clinical predictors of lithium response and identified five that were consistently associated 
with lithium response across studies.  These included a pattern of mania-depression-
interval in bi-phasic episodes (so-called MDI polarity sequence) and older age at onset 
associated with better response, and high number of hospitalizations, a pattern of 
depression-mania-interval (i.e., DMI polarity sequence), and continuous cycling associated 




treatment response were relatively small.  In a later review, Tighe and colleagues (16) re-
examined the data from Kleindeinst and colleagues along with new data that has since been 
published and generally re-affirmed the conclusions. 
        The findings from our study agree with some, but not all, of the conclusions from 
these recent reviews.  Similar to the reviews, we found that poor functioning prior to 
treatment (as captured by unemployment in previous studies), negative life events, and 
personality disturbances were associated with poor treatment response.  On the other hand, 
we found no evidence for an association of treatment response with age at onset, number 
of hospitalizations or rapid cycling.  We did not have a direct measure of social status; 
however, we did have the number of years of education, which is a reasonable proxy for 
social status, but was not associated with treatment response.  We also did not have 
sufficient data to examine associations with episode pattern, which is a compelling 
observation that has been implicated by previous studies.   
        Unique to our study, we found intriguing associations of treatment response with 
current anxiety symptoms as well a history of migraine, suicidal ideation/attempts, and 
mixed episodes.  The observation that symptom level, but not lifetime diagnosis, of anxiety 
was associated with treatment response echoes findings from the NIMH Collaborative 
Depression Study that the severity of anxiety is predictive of long-term morbidity in BD 
(17). With regard to migraines, it has been shown that the prevalence of migraines in 
patients with BD is 2–3 times higher than in the overall population.  Moreover, antiepileptic 
drugs, such as valproate, are used to treat migraines whereas lithium has no indication in 
their prophylactic treatment.  Thus, co-morbid migraine could mark an etiologically 




suicidal behavior, we observed a “dose-response” relationship between the severity of 
suicidal behavior and increased risk for treatment failure, which lends further credence to 
the finding.  However, this finding should not be taken as a reason for not prescribing 
lithium to suicidal patients, because lithium has been shown to be effective in reducing the 
risk of suicide (19,20), even in people who do not experience full mood stabilization on 
lithium (21).  Interestingly, we found that the association with suicidal behavior was 
noticeably stronger in the maintenance phase of the study, although a formal interaction 
test of a difference by study phase was not significant. The interpretation of this finding is 
unclear and warrants further investigation. 
        If our findings are validated, they may help complete a clinical picture for the types 
of patients that do not respond well to lithium treatment and lead to clues about the 
underlying mechanisms that explain poor response.  However, these findings should be 
interpreted in the light of certain limitations of the study.  At least three such limitations 
merit further consideration.  First, a sizable proportion of the patients were withdrawn or 
terminated from the study for a variety of reasons before the pre-specified endpoints of 
treatment failure or completion of all visits.  The survival analysis assumed the risk of 
treatment failure for these patients was the same as for those who stayed on the study per 
protocol.  It is possible this assumption was not true, and patients who did not complete the 
study per protocol did so because they were different somehow and possibly experiencing 
complications that were a precursor to treatment failure.  Consistent with this, we did 
observe differences in certain baseline characteristics for those who did not complete the 
study per protocol.  These individuals tended to be younger (p=0.091), non-Caucasian 




we carried out two alternative analyses of the data and the findings were remarkably similar, 
suggesting the findings were robust to assumptions made by the survival analysis.   
        Second, in order to broaden the available population for study, we included patients 
who were naïve to lithium as well as those who may have taken lithium in the past or were 
currently on it.  It is likely the response trajectories while on study would be different for 
these patients.  Indeed, over one-quarter of the patients entered the study stable on lithium 
monotherapy and their treatment outcomes were notably better.  To account for these 
differences, we tightly controlled for lithium status in the analysis, so that inferences about 
the associations with treatment response would not be confounded by these differences.  
        Finally, the sample size may not have provided sufficient power to detect significant 
associations with important clinical predictors with smaller effect sizes.  However, we 
emphasize this is one of the largest prospective studies specifically designed to investigate 
predictors of lithium response.  Indeed, it is the only such study that sought to treat patients 
with monotherapy in order to more firmly link treatment predictors with lithium response 
unclouded by the use of other psychotropic medications that are frequently taken by 
patients with BD.  This is a unique and noteworthy strength of this study. 
        Given the devastating burden of BD, there is considerable motivation to develop more 
effective strategies for treating the disorder.  Lithium is an inexpensive and effective 
treatment, but it does not work for everyone.  It would be of tremendous clinical benefit if 
we could identify predictors of who will respond to lithium before starting treatment.  This 
study provides new evidence that certain clinical factors could be used to help with such 
predictions.  Interestingly, we found that a model which included these clinical factors 




than the null.  The hope is that we will be able to improve upon this by developing more 
sophisticated prediction models that incorporate both clinical and biological (e.g., 
neuroimaging, neurophysiology and molecular) markers.  This is the goal of the PGBD, 
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Table 1. Clinical predictors examined for association with treatment response  
Baseline Symptoms Comorbidity 
Anxiety symptomsa Comorbid alcohol abuse/dependencec 
Hypermotor activityb Comorbid substance abuse/dependencec 
Irritability and aggressivenessb Comorbid anxiety disorderc  
Clinical History Comorbid personality disorderc 
Age of onsetc Functioning 
Chronicity of affective disorderc Disability at baseline: impairmentf 
Chronicity of substance abusec Disability at baseline: family/home lifef 
History of delusionse Disability at baseline: social lifef 
History of auditory hallucinationse  Disability at baseline: totalf 
History of visual hallucinationse Disability at baseline: work/schoolf 
History of any hallucinationse Functioning during most severe depressionc 
History of headaches lasting 4 to 72 hoursd  Functioning during most severe maniac 
History of migrainesd Functioning overallc 
History of suicidal thought/behaviorc Years of educatione 
History of suicide attempte  Marital statuse 
Affective psychosisc Life Events 
Independence of psychosis episodesc Childhood life eventsg 
Mania type: irritable vs. elatede  Childhood physical abuseg  
Number hospitalizations: inpatiente  Life events at last visit: totalh 
Number hospitalizations: inpatient + daye Life events at last visit: negativeh 
Presence of mixed episodesc  Life events at last visit: positiveh 
Presence of rapid cyclingc  Family History 
 First degree history completed suicidei 
 First degree history bipolar disorderi  
 First degree history depressioni 
a Hamilton Anxiety Rating Scale (HAM-A) administered by clinician at the baseline visit 
b Clinician-Administered Rating Scale for Mania (CARS-M) administered by clinician at the baseline visit  
c Final Best Estimate form of the DIGS evaluation administered by clinician at the screening visit 
d Migraine Questionnaire self-rated at the screening visit 
e Diagnostic Interview for Genetic Studies (DIGS) administered by clinician at the screening visit 
f Sheehan Disability Scale self-rated at the baseline visit 
g Childhood Life Events scale self-rated at the screening visit 
h Life Events Questionnaire from last study visit 




















Age, mean years ± SD  43.84 ± 15.48 42.20 ± 13.32 41.66 ± 14.60 0.53 
Sex, n (%)     
Male  41 (46.59) 51 (50.50) 67 (42.95) 0.49 
Female  47 (53.41) 50 (49.50) 89 (57.05)  
Race, n (%)    0.06 
Asian  2 (2.27)  1 (0.99)  4 (2.56)  
Black  7 (7.95)  7 (6.93)  28 (17.95)  
White   77 (87.50)  89 (88.12)  115 (73.72)  
More than one race 2 (2.27) 4 (3.96) 9 (5.77)  
Ethnicity, n (%)    0.94 
Hispanic  3 (3.41)  3 (3.00)d  6 (3.85)  
Non-Hispanic  85 (96.59)  97 (97.00)  150 (96.15)  
Li Status, n (%)e    <0.001 
Li monotherapy 56 (63.64)  16 (15.84) 25 (16.03)  
Li plus other meds  19 (21.59) 47 (46.53) 58 (37.18)  
Not on Li  13 (14.77) 38 (37.62)  73 (46.79)  
Site, n (%)    0.001 
UCSD 7 (7.95) 11 (10.89) 11 (7.05)  
Case Western 10 (11.36) 21 (20.79) 40 (25.64)  
Indiana  8 (9.09) 12 (11.88) 6 (3.85)  
Johns Hopkins 5 (5.68) 8 (7.92) 28 (17.95)  
Bergen 10 (11.36) 8 (7.92) 21 (13.46)  
Chicago 2 (2.27) 4 (3.96) 11 (7.05)  
Iowa 12 (13.64) 9 (8.91) 13 (8.33)  
Michigan 17 (19.32) 14 (13.86) 10 (6.41)  
Penn 4 (4.55) 4 (3.96) 8 (5.13)  
Dalhousie 12 (13.64) 9 (8.91) 5 (3.21)  
Mayo Clinic 1 (1.14) 1 (0.99) 3 (1.92)  
a Includes subjects who completed all study visits or achieved maintenance and still active on study 
b Includes subjects who failed to remit or who relapsed on lithium monotherapy 
c Includes subjects who withdrew from the study or were terminated for other reasons 
d The ethnicity of one patient was unknown 









Table 3. Hazard ratio (HR) associations between clinical predictors and treatment response 
 
# treatment failures / total 
person-daysa  
HR (95% CI); p-value 
Baseline Anxiety Symptoms (cont.)b  98 / 105053 1.05 (1.03 – 1.08); p<0.001 
Chronicity of Affective Disorder   
Non-Chronic  32 / 65683 1.00 
Chronic  58 / 28693 2.92 (1.76 – 4.83); p<0.001 
History of Migraine   
No  71 / 86811 1.00  
Yes  28 / 17094 1.62 (1.03 – 2.55); p=0.037 
History of Suicidal Behavior   
None 22 / 42134 1.00 
Suicidal Ideation  32 / 30103 1.65 (0.95 – 2.86); p=0.077 
Suicide Attempt 36 / 22915 2.03 (1.16 – 3.53); p=0.012 
History of Mixed Episodes   
No 46 / 65213 1.00 
Yes 44 / 28388 1.60 (1.01 – 2.53); p=0.046 
Overall Functioning    
Not Disabled 46 / 67890 1.00 
Disabled 39 / 24587 1.80 (1.13 – 2.86); p=0.013 
Disability at Baseline: Total (cont.)b 97 / 102885 1.06 (1.03 – 1.08); p<0.001 
Disability at Baseline: Impairment   
No 36 / 68392 1.00 
Yes 61 / 35389 1.85 (1.15 – 2.97); p=0.011 
Childhood Physical Abuse   
No 61 / 82077 1.00 
Yes 37 / 21477 1.97 (1.28 – 3.03); p=0.002 
Negative Life Events (cont.)b 91 / 94193 1.02 (1.00 – 1.03); p=0.020 
a This is the number of treatment failures defined as failure to remit or a relapse on lithium monotherapy 
over the total number of days of follow-up from study entry to the last visit for all patients in the specific 
category; sums of treatment failures and person-days of follow-up may differ across covariates due to 
missing data. 
b For continuous covariates the number of treatment failures per total person-days of follow-up is shown for 








Supplemental Table 1. Hazard ratio (HR) associations between clinical predictors and treatment response 
over the stabilization and maintenance phases of the study. 
 




HR (95% CI) 
Events/ 
person-days 









     
Non-Chronic 11 / 14592 Ref 21 / 51091 Ref  
Chronic 43 / 12929 3.96 (1.94-8.12) 15 / 15764 1.83 (0.84-4.00) 0.50 (0.19-1.32) 
History of 
Migraine 
     
No 40 / 22348 Ref 31 / 64463 Ref  
Yes 18 / 7575 1.37 (0.77-2.42) 10 / 9519 1.80 (0.86-3.74) 1.48 (0.60-3.67) 
History of 
Suicidal Behavior 
     
None 14 / 9692 Ref 8 / 32442 Ref  
Ideation 19 / 9116 1.37 (0.68-2.77) 13 / 20987 2.55 (1.01-6.39) 1.63 (0.53-5.01) 
Attempt 21 / 8848 1.37 (0.69-2.72) 15 / 14067 4.30 (1.70-10.90) 2.35 (0.77-7.11) 
History of Mixed 
Episodes  
   No 
   Yes 
 
 
24 / 15602 







22 / 49611 











   Not Disabled  
   Disabled 
 
22 /16894 





24 / 50996 
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14 / 13472 







22 / 54920 











   No  
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33 / 21008 







28 / 61069 






















Figure 1. Consort flow diagram of patients in the Pharmacogenetics of Bipolar 














Figure 2. ROC curves for the prediction of lithium treatment failure over a two-year 
period for a base model that included the base factors controlled for in all analyses 
(age at study entry, sex, race, and lithium status upon entry into the study) and a full 
model that included these base factors, all clinical predictors that were individually 















Genetic Predictors of Response to 
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5.1 Abstract  
 
Background 
Given the devastating burden of bipolar disorder (BD), there is considerable motivation to 
develop effective strategies for treating the disorder.  Lithium is an inexpensive and 
effective option, but it does not work for everyone.  This paper seeks to identify genetic 





A multi-site prospective trial of lithium treatment in bipolar 1 disorder was carried out.  
Patients were gradually discontinued from all other psychotropic medications and 
stabilized on lithium monotherapy over four months.  Once a sustained clinical remission 
(defined by a score of <3 on the CGI for four weeks) was achieved, patients were followed 
for up to two years to monitor clinical response.  DNA was collected at the baseline and 
SNP genotyped for subsequent genome-wide association study (GWAS).  Lead SNPs from 
previous studies, genetically imputed gene expression levels using reference data from 
post-mortem brains samples of the limbic system (i.e., a transcriptome-wide association 
study or TWAS), and polygenic risk scores for psychotic illnesses were all tested for 
association with lithium response.  Cox proportional hazard models were used to examine 
the relationship between these genetic predictors and time on study until treatment failure 
in a final sample of 319.   
Results 
None of the lead SNPs or imputed gene expression levels were associated with treatment 
response after correction for multiple testing.  However, enrichment analyses of nominally 
significant genes from the TWAS  (n=344 for the amygdala;  n=394 for the sACC) 
identified several significant (FDR<0.05) pathways. Of particular interest were the SET1A 
(CORUM:6469) and SET1B (CORUM:6470) gene sets and negative regulation of Wnt 
signaling pathway (GO:0030178).  Bipolar PRS were also inversely associated with 
treatment failure during the stabilization phase (HR: 0.69; 95% CI: 0.48-0.98), but not 





Despite the relatively small sample size by conventional GWAS standards, we observed 
several intriguing findings which suggested that genetic variation in histone methylation 
and Wnt signaling pathways may influence lithium treatment response.  Both of these 
pathways have been implicated previously in lithium’s therapeutic mechanisms of action.  
In addition, there was modest evidence that increasing PRS for bipolar disorder may be 
associated with better treatment response during treatment stabilization.  Larger samples 
will be needed to confirm these findings and determine whether they may be used  
clinically to distinguish which patients will do well on lithium before starting therapy. 
 
5.2 Introduction  
 
        Bipolar disorder (BD) is a severe mental illness that affects between 1 to 4.4% of the 
population worldwide, depending on how broadly you define the disorder  [1, 2].  It is 
characterized by an episodic course of illness that alternates between extreme mood states 
of mania and depression, and it is associated with longstanding disability [3].  It imposes a 
significant burden on individual sufferers as well as on overall public health.  It has been 
estimated that the costs of care of individuals with bipolar disorder in the US alone exceeds 
$45 billion per year [4]. 
        Lithium is recommended as a first-line therapy by established treatment guidelines 
[5], and it has been reported that approximately 30% of patients treated with it respond 
well to long-term treatment [6].  However, its use associated with certain side effects [7] 
that range from less (e.g., tremors, dry mouth, and increased urination) to more serious 
(e.g., thyroid and kidney toxicities).  Lithium has a narrow therapeutic window requiring 




threatening toxicity.  Due to these complications, and the aggressive efforts of 
pharmaceutical companies to market alternative treatments [9], several other classes of 
drugs that have shown some efficacy in BD have been increasingly prescribed to treat 
patients with BD.  These include certain anticonvulsants (e.g., valproic acid and 
lamotrigine) and other second generation antipsychotics (most notably, quetiapine, 
aripiprazole, and risperidone).  As a result, patients often endure an extended period of trial 
and error to find the right medication, during which time they may continue to suffer 
needlessly and run the risk of significant adverse consequences, including suicide [10].     
        There is growing interest in developing biomarkers that can help predict how patients 
with BD might respond to the different available medications before they initiate treatment 
so that the right prescriptions can be tailored to the individual patients[11].  With regard to 
lithium, there would be clear and considerable benefit in being able to identify the sub-set 
of patients who might respond well to lithium so they could be started on it before trying 
other medications which may or may not be as effective for them.  
        There is evidence to suggest that genetics factors help shape response to lithium 
treatment for BD.  It has been reported that patients who respond well to lithium are more 
likely have a family history of BD compared to poor responders [12], and good responders 
tend to aggregate within families [13, 14].  Motivated by this evidence, at least five studies 
using modern genome-wide association study (GWAS) methods have been carried out to 
identify genetic variants associated with lithium response.  These studies have reported 
mixed findings.  They were either retrospective in design, where lithium response was 




designed to test genetic markers for treatment response.  As a result, further study of the 
genetics of response to lithium treatment is clearly warranted. 
This paper reports findings from the analysis of GWAS data from the The 
Pharmacogenomics of Bipolar Disorder (PGBD) Study.  The PGBD was a multi-site, 
prospective study carried out as part of the Pharmacogenomics Research Network (PGRN) 
and sponsored by the NIGHMS in collaboration with the NIMH.  The goal of the study 
was specifically to test for genetic markers of response to monotherapy with lithium over 
two years of follow-up.  Because the overall sample size was small relative to current 
GWAS standards, we focused on tests of lead SNPs implicated by previous GWAS of 
lithium response, individual genes across the genome using a  novel transcriptome-wide 
association study (TWAS) approach that reduces the multiple testing burden and yields 
findings that point more directly to biologic mechanisms, and specific polygenic risk scores 
for psychotic mental illnesses for which lithium may be effective. 
 
5.3 Methods  
Study Design 
        The details of the PGBD Study have been described elsewhere [21].  Briefly, it was a 
prospective, multi-site study in which patients with BD were stabilized on lithium 
monotherapy and followed for up to two years or until recurrence of their illness.  Patients 
were enrolled at nine sites in the United States and two internationally.  All study 
procedures were approved by local Institutional Review Boards (IRBs), and all patients 




        Patients were included in the study if they: 1) had bipolar I disorder in any phase of 
illness; 2) were naïve to or not presently on lithium and had at least one affective episode 
meeting DSM-IV criteria in the last 12 months, or were currently on lithium and did not 
have any history of mood episodes meeting DSM-IV criteria in the last 6 months; 3) were 
able to give informed consent; 4) were 18 years or older; and 5) were currently 
symptomatic, as defined as a CGI-S score of at least 3 (mild severity), unless the patient 
entered the study already stable on lithium monotherapy.  Women of child-bearing 
potential were included if they agreed to use adequate contraception and inform their doctor 
at the earliest possible time of their plans to conceive.   
        Patients were excluded if they: 1) were unwilling or unable to comply with study 
requirements;  2) had renal impairment (serum creatinine >1.5 mg/dL);  3) had thyroid 
stimulating hormone (TSH) over >20% above the upper normal limit or, if on thyroid 
medication, had not been euthyroid for at least 3 months before the first visit; 4) were 
currently in crisis such that inpatient hospitalization or other crisis management should take 
priority; 6) met criteria for physical dependence requiring acute detoxification from alcohol, 
opiates or barbiturates; 7) were pregnant or breastfeeding; 8) had participated in a clinical 
trial of an investigational drug within the past 1 month, or 9) had a history of lithium 
toxicity, not due to mismanagement or overdose, that required treatment. 
        All patients enrolling in the study were either already on lithium monotherapy or they 
went through a stabilization phase that lasted a maximum of 16 weeks – and included visits 
every other week for the first 8 weeks and one visit per month for the next two months – 
during which they were stabilized on lithium monotherapy.  They were then observed in 




a Clinical Global Impression of Severity Scale (CGI-S) score of <3 (mildly ill) for at least 
4 weeks.  After the observation phase, the patients entered a two-year maintenance phase, 
during which they were assessed every 2 months to monitor their on-going clinical 
response.  Throughout the follow-up, patients were allowed to take a benzodiazepine for 
anxiety and/or zolpidem for sleep.  
 
Clinical Outcomes 
        Patients were followed until one of three endpoints: 1) they completed all study visits 
over two years of the maintenance phase (or had achieved the maintenance phase and were 
still active in the on-going study by the date of the data freeze); 2) they were terminated 
from the study before completion of all visits because of failure to achieve (i.e., failure to 
remit) or maintain (i.e. relapse) stabilization on lithium; or 3) they were terminated from 
the study for other reasons.  Failure to remit was defined by the inability to achieve 
clinically sustained remission (where remission was documented as described above) by 
the end of the observation phase or based on clinical judgment that the patient was unable 
to adequately stabilize on lithium monotherapy.  Relapse was evaluated using the Mood 
Episode Checklist which summarizes DSM-IV criteria for mania and depression and was 
collected at each visit during the maintenance phase. Relapse was defined by the following:  
1) met criteria for mania and had a CGI-S of 5 (markedly ill) or greater; 2) met criteria for 
a major depressive episode with 4 week duration; 3) met criteria for a mixed episode with 
CGI-S of 5 or greater; 4) psychiatric hospitalization for a mood episode was required; or 




change in medication was required. Episodes of hypomania by itself without impairment 
of function were not considered relapses.  
 
Genetic Data 
Blood samples were collected from all patients at the baseline visit for investigation 
of genetic and other molecular predictors of response to lithium treatment.  Samples were 
genotyped using the Illumina PsychArray for subsequent trans-ethnic GWAS analyses.  
SNP genotypes were called using standard software, and extensive quality control 
procedures were carried out following the Psychiatric Genomics Consortium best practices 
and the RICOPILI pipeline [22].  SNPs and subjects were retained for downstream analyses 
using the following QC parameters: SNP missingness <0.05 (before subject removal); 
subject missingness <0.02; autosomal heterozygosity deviation (|Fhet|<0.2); SNP 
missingness<0.02 (after subject removal); difference in SNP missingness between cases 
and controls <0.02; and SNP HWE (P > 1e−6 in controls and P > 1e−10 in cases). Subjects 
were further screened for relatedness to any other subject (closer than 2nd degree, π<0.2), 
unusual homozygosity, sex mismatch, and principal component analysis (PCA) ancestry 
outliers. Imputation was carried using the pre-phasing/imputation stepwise approach 
implemented in IMPUTE2 / SHAPEIT (chunk size of 3 Mb and default parameters) with 
the 1000 Genomes Phase 3 multi-ancestry reference panel [23]. 
  
TWAS Data 
        We examined gene level associations using a transcriptome-wide association study 




with lithium response. The data to impute genetically determined gene expression levels in 
the PGBD sample came from an RNA-sequencing study of a post-mortem brain collection 
from the Lieber Institute for Brian Development.  This collection includes samples from 
two brain regions implicated in BD - the amygdala (n=243) and the subgenual anterior 
cingulate cortex (sACC; n=268).  RNA-sequencing of these samples have been described 
elsewhere (Zandi et al., In Preparation).  Briefly, libraries were constructed using Illumina 
TruSeq Stranded Total RNA Ribo-Zero sample Prep Kit and then sequenced using an 
Illumina HiSeq 2000.  Reads were mapped to the hg38/GRCh38 human reference genome 
with the splice-aware aligner HISAT2 version 2.0.4. The program featureCounts was then 
used to derive a read count matrix for gene expressed features based on GENCODE release 
25 (GRCh38.p7) annotation.  Genome-wide SNP genotype data was generated on these 
samples using several different Illumina SNP chips, and all samples were subsequently 
imputed using 1000 Genomes Phase 3 multi-ancestry reference panel. 
        We analyzed this data to generate predictive models for imputing gene expression 
levels with SNPs in cis (+/-500kb) within each gene.  We generated two sets of predictive 
models, one for each brain region, and retained for downstream analyses only those models 
for genes with significant cis SNP heritability (p-value < 0.01).  Building on prior work by 
Collado-Torres et al. in schizophrenia [24],  we employed four FUSION-based methods to 
generate predictive models controlling for SNP and expression principle components: best 
linear unbiased prediction (BLUP), elastic net, lasso and top1.  SNP weights were 
constructed from 8124 (genes)  4 (FUSION methods) predictive models for sACC and 
8039 (genes)  4 (FUSION methods) predictive models for amygdala after heritability 




highest 5-fold cross-validated R squared value among the models that have non-zero 
estimates.  For both the amygdala and sACC, BLUP was selected most often for 3014 out 
of 8039 models and 3142 out of 8124 models, respectively.  Elastic net was selected least 
often for 757 out of 8039 models and 727 out of 8124 models, respectively (Supplemental 
Figure 1).  We used the best predictive model for each gene to impute expression levels in 
the PGBD sample by taking the inner product of the SNP weights and the individual-level 
genotype data.  The imputed gene expression levels were then used in downstream analyses 
of the PGBD sample as described below.      
 
Polygenic Risk Scores 
Summary statistics of association results from the latest Psychiatric Genomic 
Consortium (PGC) GWAS of schizophrenia [25] and BD [26] were used to compute 
polygenic risk scores (PRS) for each patient in the PGBD sample. PRSice was used to 
explore different p-value thresholds for selecting SNPs from the PGC discovery summary 
results.  Based on an examination of the results across the models tested, we reported results 
based on a threshold of p<0.04.  Given that the PGC GWAS were based almost exclusively 
on northern European samples, we additionally carried out a sensitivity analysis in which 
we generated PRS scores just for the Caucasian samples in PGBD using these samples to 
clump SNPs for selection.  
 
Survival Analysis 
We used Cox Proportional Hazard models in a time-to-event framework to analyze 




SNPs, imputed gene expression levels, or polygenic risk scores.  Time was operationalized 
as the time from entry into the study until the time to treatment failure - defined as the time 
of the last visit at which the patient was determined to have failed to remit or to have 
relapsed - or the time of the last visit in the on-going study if the patient did not experience 
a treatment failure.  Models were tested using time over the entire course of the study and 
then stratified by time over the stabilization phase (which we defined here as including the 
observational phase described above) versus the maintenance phase.  All models controlled 
for potential confounders including age at study entry, sex, race, and lithium status upon 
entry into the study.  These variables were selected from the available data because they 
are important socio-demographic factors that experience indicated may be relevant and/or 
they were found to differ with treatment outcome.  Race was defined based on self-report 
with the following categories: African American, Asian, Caucasian, more than one race.  
Self-report was used to be consistent with prior reports of findings from the PGBD, and it 
was found to map reasonably well on to genetically determined ancestry as visualized by 
principal component analysis of the SNP genotype data (Supplementary Figure 2). 
 
Pathway Analysis 
  We performed gProfiler pathway analysis [27] on the nominally significant (p-
value < 0.05) results from the TWAS analysis to check for pathway enrichment. gProfiler 
uses a hypergeometric test to evaluate for enrichment of pathway genes in a user-supplied 
list of genes.  Pathways tested come from GO (including cellular components, molecular 
functions and biological processes) [28, 29]; the KEGG [30] and Reactome [31] databases; 




transcription factors from TRANSFAC [33]; information about protein complexes and 
protein–protein interaction networks from the CORUM database [34] and BioGRID [35]; 
protein expression data from the Human Protein Atlas [36]; and gene annotations of 
physiological and disease phenotypes from the Human Phenotype Ontology [37] and 
Online Mendelian Inheritance in Man (OMIM) resource [38]. We supplied as the 
background for these enrichment tests the lists of all genes tested in the TWAS separately 
for the sACC and amygdala.  
 
5.4 Results  
We included in the analysis all patients enrolled in the study who completed at least 
four weeks of follow-up and had evaluable genotype data, which after all QC procedures 
included 319 patients.  Table 1 shows basic socio-demographic characteristics of the study 
sample broken down by the final outcome status of the patients, that is if they completed 
the study per protocol, experienced a treatment failure, or were terminated for other reasons.  
There were no significant differences in age, sex or race between these three broad 
outcomes.  Patients who entered the study stable on lithium monotherapy were significantly 
more likely to complete the study compared to others.  There were also significant 
differences between the sites in the outcomes achieved by the patients, but these differences 
were largely explained by the proportion of patients at each site that entered the study stable 
on lithium, highlighting the importance of controlling for this potential confounder in 






        We first tested for associations with seven different lead SNPs that have been 
implicated by previous GWAS of lithium response.  Table 2 shows hazard ratio (HR) 
associations between these lead SNPs and lithium response in the current study over the 
full follow-up, and then stratified by the stabilization and maintenance phases  of the study.  
None of the lead SNPs were significant predictors of response over the full follow-up 
(Table 2).  After stratification of the follow-up period, two SNPs located in an intron of 
GADL1 from the Chen et al. study [16], rs17026688 and rs17026651, were significantly 
associated with response during the stabilization phase.  However, the minor allele 
frequencies of these two SNPs were exceedingly rare in our sample such that the tests of 
associations were highly unstable and, thus, unreliable. 
  
TWAS 
        We next carried out gene level tests in which we examined the associations between 
genetically determined gene expression levels and response to lithium treatment.  We used 
as the reference for these analyses one of the largest available post-mortem brain samples 
with data on two brain regions that have been implicated in BD, the amygdala and the 
subgenual anterior cingulate cortex (sACC).   
        Examination of Q-Q plots for the gene level association results suggested there was 
no inflation of test statistics (Supplementary Figure 3).  If anything, there was some 
deflation, likely due to the small sample that was under-powered.  Figure 1 shows 
Manhattan plots of the results for the full follow-up, as well as the stabilization and 
maintenance phases.  No genes were significantly associated with lithium response over 




correction.  A total of 344 genes were nominally significant from the amygdala, and 394 
genes were nominally significant in the sACC.  Of these, there were only 7 genes that were 
in common between the two brain regions, including PSMC3, ACO93838.4, CCDC88B, 
CSF1, BCL11B, Y_RNA, and MAD2L2.   
        Stratification by study phase (stabilization vs maintenance) also did not yield any 
genome-wide significant findings.  Of the genes nominally associated with failure to remit 
in the stabilization phase or relapse in the maintenance phase, 17 and 14 genes were in 
common for amygdala and sACC, respectively. In addition, 390 (amygdala) and 380 
(sACC) genes were unique to stabilization phase and 334 (amygdala) and 378 (sACC) 
genes were unique to maintenance phase.  
 
Pathway analysis 
        To infer the potential biological processes underlying the TWAS associations with 
lithium response, we inputted the nominally significant genes for the amygdala and sACC 
respectively into gProfiler for functional profiling.  For these analyses, we only considered 
the results from full study follow-up.  Interestingly, several distinct sets of pathways were 
significantly enriched (FDR<0.05) in the associated genes across the two brain regions 
(Table 3 and Figure 2).  For the amygdala, there was a cluster of enriched pathways from 
the CORUM database, which captures information about protein complexes and protein–
protein interaction networks.  A common theme for these enriched pathways was they 
included protein complexes involved in histone methyltransferase and acetyltransferase 
activity.  Prominent among these were the SETD1A, SETD1B, and WRAD complexes, 




and either directly or indirectly involve SETD1A which has previously been associated 
with schizophrenia [39].  For the sACC, several GO biological process pathways were also 
enriched revolving around cellular response to stimuli (GO:0051716, GO:0050896, 
GO:0048584); signaling and signal transduction (GO:0023052, GO:0007165, 
GO:0007166); and particularly Wnt signaling (GO:0030178).  
 
Polygenic Risk Scores 
        Finally, we tested for associations with polygenic risk scores derived for severe 
psychotic mental illnesses, including bipolar disorder and schizophrenia, which we 
hypothesized may influence treatment response to lithium.  Neither of the PRS for BD nor 
schizophrenia were significantly associated with lithium response over the full study 
follow-up (Table 4).  However, increasing PRS for BD was inversely associated with 
failure to remit during the stabilization phase (hazard ratio [HR]: 0.69; 95% confidence 
interval [CI]: 0.48-0.98). The inverse association remained significant when we restricted 
the analysis to patients of European ancestry (HR: 0.76; 95% CI: 0.58-1.00) in a sensitivity 
analysis.  Increasing PRS for schizophrenia was also inversely associated with failure to 
remit during the stabilization phase, but this was not significant (HR: 0.54; 95% CI: 0.28-




In this study, we aimed to identify genetic predictors of response to lithium 




existing studies to test for such associations using a prospective study design in which the 
goal was to treat patients with lithium monotherapy in order to isolate effects specific to 
this treatment.  Due to the relatively small sample size for GWAS, we decided to focus on 
tests of lead SNPs that have been reported by previous studies, as well as more global tests 
of individual genes using TWAS and genome-wide polygenic risk for severe mental 
illnesses that we hypothesized may be related to treatment response.  Two key findings 
emerged from these analyses.  First, although there were no genome-wide significant 
findings with individual genes using TWAS, several intriguing pathways were found to be 
enriched among the top results.  These included pathways related to histone methylation 
and acetylation and Wnt signaling, which have been implicated previously in lithium 
mechanisms of action.  Second, we found that increasing polygenic risk for BD was 
associated with lower risk of treatment failure, at least over an initial stabilization phase of 
treatment.  These findings warrant further investigation both as clues to the mechanisms 
that may underlie treatment effectiveness with lithium in BD and as potential clinical 
predictors of treatment response. 
At least five GWAS of lithium treatment response in BD have been previously 
reported.  In 2009, Perlis and colleagues conducted a GWAS of mood disorder recurrence 
among 458 lithium treated patients with bipolar I (BDI) and bipolar II (BDII) disorders 
from the STEP-BD cohort and a replication sample of 359 BD patients.  There were no 
genome-wide significant results, but the most compelling finding spanned GRIA2, an 
AMPA receptor involved in glutamatergic signalling [15].  In 2014, Chen and colleagues 
reported results from a GWAS on a subset of 294 BDI patients on lithium treatment from 




Consortium.  Two SNPs in high linkage disequilibrium located in the introns of GADL1 
showed the strongest associations and reportedly had a sensitivity of 93% for predicting 
lithium response [16].  In 2015, Song and colleagues reported a genetic variant in SESTD1 
associated with lithium-responsive BD from a GWAS comparing lithium responders with 
healthy controls from Sweden and the UK, including 1,639 self-reported responders versus 
8899 controls and 323 clinically-documented responders versus 6,684 controls [17].  
Finally, in 2016 and 2018, there were two reports from the Consortium on Lithium 
Genetics (ConLiGen) which conducted GWAS with 2,653 BD patients retrospectively 
characterized for lithium response using the Alda Scale [18]. These studies reported finding 
associations with a locus that contains two long non-coding RNAs (lncRNAs) genes, 
AL157359.3 and AL157359.4 [19], as well as an inverse association between increasing 
polygenic risk scores for schizophrenia and poor response to lithium [20]. 
        We were unable to credibly replicate any of these prior associations, although the 
sample size may have limited our power to detect these associations.  This was especially 
true for the findings from the Chen et al. [16] study in an Asian sample, as the minor allele 
frequencies of the implicated SNPs from these samples were very rare in the PGBD sample, 
which was mostly Caucasian and African American.  Because the minor allele frequencies 
were so low, the estimated associations were highly unstable and, therefore, not reliable.  
Intriguingly, there were trends of inverse associations between SNPs reported by Song et 
al. [17] and Hou et al. [19] studies, especially during the stabilization phase of treatment, 
but these findings were not significant and cannot be considered a replication. 
Challenges with interpretation of GWAS findings have motivated the development 




identify associated genes by testing variability in genetically determined gene expression.  
Despite recently suggested vulnerabilities [40], this approach aims to identify associated 
features underlying lithium response directly, rather than single nucleotide variants with 
often ambiguous or uncertain annotation and functionality.  The TWAS approach may also 
increase the power over traditional GWAS to identify genetic associations by reducing the 
burden of multiple testing. 
In this study, we used one of the largest available samples of post-mortem brains 
from the Lieber Institute collection to generate more powerful gene expression prediction 
models from amygdala and sACC.  In the healthy brain, the performance of emotional tasks 
recruits the limbic neural system, which is comprised of the orbital and medial parts of the 
prefrontal cortex, including the sACC, and subcortical structures, including the amygdala 
and ventral striatum [41, 42].  For BD, we have seen consistent findings in the 
neuroimaging literature that allude to an etiological model in which the abnormalities in 
the structure and function of the amygdala play a role but also depend on the failure of 
prefrontal cortical regions to modulate activity [43]. Structural brain abnormalities in the 
prefrontal cortex have also been confirmed in postmortem studies and with structural MRI 
[44].  The sACC, as an example, was reduced in volume in patients with BD with a family 
history of affective disorder [45, 46].  These imply the involvement of complex 
neurocircuitry in BD neuropathophysiology.  It has been reported that BP patients with 
previous lithium treatment had greater hippocampal and amygdalar volumes than those 
without lithium exposure [47].  Lithium has also been proposed to have neuroprotective 




that motivated us to use data from the amygdala and sACC as our reference for the TWAS 
of lithium response in the PGBD.  
 None of the individual gene tests were significant after correction for multiple 
testing for either the amygdala or the sACC.  This is perhaps not surprising, again because 
of the relatively small sample size.  Nevertheless, we did observe significant enrichment 
of several intriguing gene sets among the top findings.  These included genes encoding 
H3K4 methyl and acetyltransferase complexes as well as those involved in Wnt signaling 
pathways.  Interestingly, the histone H3K4 methylation GO pathway (GO:51568) emerged 
as the most significant enriched pathway in bipolar disorder, and the only one that was 
significant after correcting for multiple testing, from a recent cross-disorder pathway 
analysis of existing GWAS data from the Psychiatric Genomics Consortium (PGC) [48].  
In addition, a key gene of the H3K4 methyl and acetyltransferase complexes is SETD1A 
which has been associated with schizophrenia in recent sequencing studies [39].  
Methylation and acetylation of histone proteins are well-established epigenetic changes 
involved in chromatin modification, especially at the transcription start sites of active genes.  
Lithium has been found to induce epigenetic changes through different mechanisms, 
including DNA demethylation and histones acetylation [49].  Moreover, histone 
deacetylase (HDAC), an enzyme involved in histone deacetylation, is recognized as the 
primary target of valproic acid, which also has efficacy as a mood stabilizer [50].  Thus, 
there is evidence that lithium’s mechanism of action may, at least partially, be mediated 
via chromatin remodeling, and the current findings suggest the possibility that genetically 
determined transcriptional levels of genes involved in chromatin modifications may 




Canonical Wnt signaling may also be crucial to lithium response in bipolar disorder 
[51, 52].  Evidence has shown that lithium action in bipolar disorder may involve both 
direct and indirect inhibition of glycogen synthase kinase-3 beta (GSK3B) (eg. [53, 
54]).  GSK3B is a serine-threonine kinase belonging to the glycogen synthase kinase 
subfamily and is a key protein in the Wnt signaling pathway.  Previous studies have 
reported that the therapeutic sensitivity to lithium may be associated with polymorphisms 
in the GSK3β promoter region [55].  In line with this, the current findings suggest that 
genetic variation determining transcriptional levels of genes involved more broadly in Wnt 
signaling may further influence lithium treatment response.  While intriguing, more 
research is needed to further investigate the role in moderating responses to lithium 
treatment of variation in genes involved in both H3K4 methylation and Wnt signaling. 
Finally, we tested whether genomewide PRS for psychotic disorders may also 
predict response to lithium treatment.  We found that increasing PRS for bipolar disorder 
was inversely associated with treatment failure, at least during the stabilization phase.  In 
other words, patients who had greater genetic risk for bipolar disorder appeared to do better 
on lithium in the short-term when initiating treatment.  This finding is in line with previous 
studies which have shown that patients with a family history of bipolar disorder respond 
better to lithium [12], and it is consistent with the notion that lithium is most effective for 
patients with a more classic form of bipolar disorder.  We also observed an inverse 
association between increasing PRS for schizophrenia and treatment failure during the 
stabilization phase, but this association was not statistically significant.  It is also 
inconsistent with a recent study from ConLiGen, which found that increasing polygenic 




More work is clearly needed to further clarify these conflicting findings.  All of the existing 
studies are probably under-powered and larger sample sizes are needed to evaluate if  PRS 
for bipolar disorder and schizophrenia can predict how patients will respond to treatment. 
In addition, future work is needed to determine if PRS for lithium response may also be 
useful for treatment prediction.  Reasonably powered PRS for lithium response are still not 
yet available, but we anticipate they will be of greater interest when they do become 
available. 
This study had several notable strengths.  Chief among them is the fact that it is one 
of the few studies to attempt to follow patients prospectively on lithium monotherapy [21].  
Patients with bipolar disorder are typically treated with multiple medications (see Chapter 
3), and as a result it can be difficult to tease apart the specific effects of individual 
medications on clinical outcomes.  By following patients on monotherapy, this allowed us 
to test genetic predictors of treatment response specifically to lithium unconfounded by the 
use of other medications.  In addition, we used a novel TWAS approach that to our 
knowledge has not been used previously to examine genome-wide predictors of lithium 
response.  Moreover, for this analysis, we were able to use for our reference one of the 
largest available post-mortem brain samples from regions of the limbic system which prior 
evidence suggests is especially relevant to the pathology in bipolar disorder. 
The study also had several important weaknesses.  Following patients on 
monotherapy is practically very challenging [21].  As a result, there was considerable loss 
to follow-up over the full course of the study (45.2%).  Our analysis assumed that the risk 
for treatment failure was the same for those patients lost to follow-up as those who stayed 




who are lost to follow-up might be more likely to go on to switch treatments.  In addition, 
the challenging nature of the study made it challenging to enroll large numbers of patients 
that are typically needed for GWAS.  As a result, the study is likely under-powered to 
detect most genetic effects on treatment response.   
Despite the challenges, we were able to identify some evidence of genetic 
associations with lithium response that merit further investigation.  Our study is among the 
first results from the PGBD trial in which we examined gene predictors of lithium response 
for patients with BD.  For those who can be effectively treated by lithium, it can be 
remarkably effective in controlling the devastating symptoms of BD.  For the more than 
40-50% of patients who do not response well, however, they may need to switch 
therapeutic regimens mid-treatment.  For either groups of patients, knowing beforehand 
whether or not they will respond well before starting treatment would offer tremendous 
clinical benefits.  Our study serves as one of the on-going attempts to identify predictors 
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Age, mean years ± SD  44.09 ± 15.55 42.85 ± 13.07 41.34 ± 14.64 0.375 
Sex, n (%)     
Male  40 (47.06) 47 (48.45) 61 (44.53) 0.830 
Female  45 (52.94) 50 (51.55) 76 (55.47)  
Race, n (%)    0.236 
African American  6 (7.06)  7 (7.22)  21 (15.33)  
    Asian  2 (2.35)  1 (1.03)  4 (2.92)  
Caucasian   75 (88.24)  85 (87.63)  105 (76.64)  
More than one race 2 (2.35) 4 (4.12) 7 (5.11)  
Ethnicity, n (%)    0.840 
Hispanic  3 (3.53)  2 (2.08)
iv
 4 (2.92)  
Non-Hispanic  82 (96.47)  94 (97.92)  133 (97.08)  
Li Status, n (%)
v
    <0.001 
Li monotherapy 55 (64.71)  15 (15.46) 23 (16.79)  
    Li plus other meds  19 (22.35) 44 (45.36) 54 (39.42)  
Not on Li  11 (12.94) 38 (39.18)  60 (43.80)  
Site, n (%)    0.001 
UCSD 7 (8.24) 11 (11.34) 10 (7.30)  
Case Western 8 (9.41) 21 (21.65) 28 (20.44)  
Indiana  8 (9.41) 12 (12.37) 6 (4.38)  
Johns Hopkins 5 (5.88) 7 (7.22) 28 (20.44)  
Bergen 9 (10.59) 8 (8.25) 17 (12.41)  
Chicago 2 (2.35) 4 (4.12) 11 (8.03)  
Iowa 12 (14.12) 9 (9.28) 12 (8.76)  
Michigan 17 (20.00) 14 (14.43) 10 (7.30)  
Penn 4 (4.71) 4 (4.12) 7 (5.11)  
Dalhousie 12 (14.12) 6 (6.19) 5 (3.65)  
Mayo Clinic 1 (1.18) 1 (1.03) 3 (2.19)  
i Includes subjects who completed all study visits or achieved maintenance and still active on study 
ii Includes subjects who failed to remit or who relapsed on lithium monotherapy 
iii Includes subjects who withdrew from the study or were terminated for other reasons 
iv The ethnicity of one patient was unknown 















Stabilization Phase  
(N=319) 
Maintenance Phase  
(N=187) 
HR 
(95% CI); p-value 
HR 
(95% CI); p-value 
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miR-548at-3p 21 0.03 
MIRNA hsa-miR-548ay-3p 
MIRNA:hsa-
miR-548ay-3p 21 0.03 
CORUM Set1A complex CORUM:6469 3 0.02 
CORUM Set1B complex CORUM:6470 4 0.04 
CORUM 
Menin-associated histone 
methyltransferase complex CORUM:1254 2 0.05 
CORUM Set1B complex CORUM:2730 2 0.05 
CORUM Set1A complex CORUM:2731 2 0.05 
CORUM PTIP-HMT complex CORUM:5195 2 0.05 
CORUM MLL3 complex CORUM:6461 2 0.05 
CORUM 
WRAD  complex (WDR5, 
RBBP5, ASH2L, DPY30) CORUM:6849 2 0.05 
CORUM NSL complex CORUM:7221 2 0.05 
sACC 
GO:BP cellular response to stimulus GO:0051716 1635 0.01 
GO:BP cell communication GO:0007154 1411 0.02 
GO:BP signal transduction GO:0007165 1294 0.02 
GO:BP signaling GO:0023052 1416 0.02 
GO:BP 
positive regulation of biological 
process GO:0048518 1423 0.02 
GO:BP response to stimulus GO:0050896 1949 0.02 
GO:BP 
cell surface receptor signaling 
pathway GO:0007166 689 0.02 
GO:BP 
positive regulation of response to 
stimulus GO:0048584 560 0.02 
GO:BP 
positive regulation of cellular 
process GO:0048522 1268 0.02 
GO:BP 
negative regulation of Wnt 
signaling pathway GO:0030178 61 0.05 
MIRNA = miRTarBase, CORUM = CORUM protein complexes, GO:BP = GO biological process 



















Table 4. Hazard ratio (HR) associations between standardized PRS predictors and lithium treatment 
response 
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Figure 1. Manhattan plots. Red line is the 5  10-6 significance line; blue line is the 5  
10-4 suggestive significance line. Genes with p-values < 0.0005 are annotated. 
(A)(B)(C) amygdala full follow-up, stabilization phase, and maintenance phase; 









Figure 2. gProfiler pathway analysis visualization from the nominally significant 
(pvalue < 0.05) genes from survival analysis on the full follow-up. Source ID 
annotation (Raudvere et al. 2019): GO:MF=molecular function; GO:BP=biological 
process; GO:CC=cellular component; KEGG=Kyoto Encyclopedia of Genes and 
Genomes; REAC=Reactome; WP=WikiPathways; TF=TRANSFAC; 
MIRNA=miRbase; HPA=Human Protein Atlas; CORUM=CORUM protein 
complexes; HP=Human Phenotype Ontology. Significant pathways (FDR adjusted p-
















Supplemental Figure 2. PCA plots for comparing PGBD sample to 1000G ancestries. 

























Supplemental Figure 3. Q-Q plots. 
(A)(B)(C) amygdala full follow-up, stabilization phase, and maintenance phase; 





























There is a long history of searching for predictors of lithium response that can help 
guide treatment decisions for patients with bipolar disorder.  Lithium is one of the most 
effective treatments for bipolar disorder and it is typically recommended as a first-line 
treatment [46].  However, only about 30% of patients respond well to lithium [47], while 
other patients typically need to switch treatments several times in order to find more 
effective medications, during which time they continue to suffer.  As a result, there is 
considerable motivation to identify predictors of who will respond well so that they can be 
started right away on lithium, while others could be started on other treatments that are 




aims to study trends in the use of lithium and identify clinical and genetic predictors of   
treatment response to help achieve the goals of precision medicine for patients with bipolar 
disorder.   
In 2005, two comprehensive systematic reviews of clinical predictors of lithium 
response were carried out by Kleindienst and colleagues in which they identified nearly 
2,000 studies published between 1966 and 2003 on this topic [17, 18].  Nearly a decade 
later, Tighe and colleagues re-examined the data from Kleindeinst and colleagues along 
with new data that had since been published and generally re-affirmed the conclusions [19].  
They identified several demographic, psychosocial and clinical predictors that appeared to 
be associated with response across the different studies, but the results were not always 
consistent and the observed effect sizes tended to be relatively small.  Few of the previous 
studies used a prospective designed to investigate predictors of lithium treatment, and none 
examined predictors of response associated with monotherapy.  
There has also been considerable interest in identifying genetic predictors of lithium 
response.  Lithium response tends to run in families, and to date five genomewide 
association studies (GWAS) of lithium response in bipolar disorder have been conducted.  
These include a study in 2009 of 458 patients with bipolar I/bipolar II disorders from the 
STEP-BD cohort [42]; a study in 2014 on a sample of 294 patients with bipolar I disorder 
on lithium treatment who were of Han Chinese descent recruited by the Taiwan Bipolar 
Consortium [21], a study in 2015 of 1639 self-reported responders and 8899 controls, as 
well as 323 clinically-documented responders and 6684 controls, from Sweden and the UK 
[22]; and two reports from the ConLiGen Consortium which has gathered lithium treatment 




studies have been largely mixed, motivating further efforts to study the genetic contribution 
to lithium treatment response. Taking the road of the advancement of our understanding of 
factors that predict lithium response, my thesis work aimed to be a small step that 
contributes to the goal of precision medicine for BD. 
Chapter 3 of this thesis characterizes trends in lithium utilization for the treatment 
of BD in the U.S. from 1996 to 2015.  In this study, we examined trends in reports of 
lithium and other medications for BD in a representative sample from the National 
Ambulatory Medical Care Survey (NAMCS), a well-characterized national survey of US 
office-based practices of physicians from different specialties, conducted annually across 
a broad range of office settings. Specifically, we examined trends in reports of lithium, 
mood-stabilizing anticonvulsants, second generation antipsychotics (SGAs) and 
antidepressants overall and in combinations in visits with a diagnosis of BD.  This study 
further documents the declining reports of using lithium for BD, and corresponding 
increase in reports of using anticonvulsants and SGAs, despite the fact that lithium is 
typically recommended as a first line therapy for BD.  One of the strengths of this study is 
that we used data from a nationally representative sample of office based clinical visits 
across the US.  In addition, these data cover a twenty-year period from 1996-2015 and were 
collected using largely consistent procedures.  This allowed us to have a relatively large 
sample to make statistical inferences, which is an advantage over past BD studies, but it 
may not be sufficiently large to detect trends in subgroups of patients.  By combining the 
data into two-year intervals, we attempted to obtain more stable results while not losing 
the ability to observe more fine scale trends, though there is likely still limited power to 




the cross-sectional nature of the NAMCS data is another limitation that makes it impossible 
to assess the prescribing patterns within individuals longitudinally, which is a feature worth 
looking into when selecting datasets for describing medication prescribing trends. 
Chapter 4 of this thesis evaluates clinical predictors associated with response to 
lithium treatment over time.  We analyzed data from the Pharmacogenomics of Bipolar 
Disorder (PGBD) Study (www.clinicaltrials.gov, NCT01272531), which is one of the first 
prospective studies of lithium treatment designed to prospectively identify clinical and 
molecular predictors of lithium response.  Specifically, we examined the relationship 
between clinical measures and time on study until failure to remit or relapse.  An advantage 
of this study is the prospective design of the PGBD trial, which is rare in the previous 
literature. This is one of the few prospective studies explicitly designed a priori to examine 
the prediction of lithium response by following patients in lithium monotherapy for up to 
two years.  Unique to our study, current anxiety symptoms, a history of migraine, suicidal 
ideation/attempts, and mixed episodes were associated with failure to respond to lithium.  
Future validation is needed to confirm these clinical predictors of treatment failure and 
their use clinically to distinguish who will do well on lithium before starting therapy.  The 
findings should be seen in the light of the limitations that include a sizable proportion of 
pre-completion withdrawals or terminations, a diversity in lithium status upon entry 
(though controlled for in all analyses) and a relatively small sample size. 
Chapter 5 evaluates the genetics predictors of lithium response in the form of lead 
SNPs that have been reported by previous studies, as well as individual genes using TWAS 
and genome-wide polygenic risk for severe mental illnesses that we hypothesized may be 




with individual genes using TWAS, several intriguing pathways were found to be enriched 
among the top results, including pathways related to histone methylation and acetylation 
and Wnt signaling that are previously implicated in lithium mechanisms of action.  We also 
found that increasing polygenic risk for BD was associated with lower risk of treatment 
failure, at least over an initial stabilization phase of treatment.  Despite using one of the 
largest available samples of post-mortem brains from the Lieber collection to generate 
more powerful gene expression prediction models, our study still suffers from lack of 
statistical power with sample size limitations from both the reference sample and the test 
sample along with other limitations of the PGBD discussed above.   
        The particular significance of the thesis work is that, although we retrospectively 
assessed the historical data on prescribing trends, we prospectively approached clinical and 
genetic evaluation of lithium response, which is a rarity in previous studies of lithium.  The 
hope is that we will be able to improve upon our prior research efforts by developing more 
sophisticated models that incorporate both clinical and biological markers to predict 
treatment response.  Given the devastating burden of BD, there is considerable motivation 
to develop more effective treatment options.  The current pandemic adds to the 
environmental factors that will inevitably contribute to more mood dysregulation, which 
may eventually lead to development of the disorder.  Lithium is an inexpensive and 
effective treatment, but it does not work for everyone.  If validated, the findings from the 
thesis work may generate clues about the underlying mechanisms that explain differential 
lithium response in treating BD and help complete the clinical picture and genetic 




them before starting treatment.  By doing so, my thesis contributes to the ultimate goal of 
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